A Phase 3 interventional study of SC treatment with IGSC, 10% with rHuPH20 followed by SC/IGSC, 10% only (safety) and SC treatment with IGSC, 10% with rHuPH20 followed by IV/IGSC, 10% only (safety) in Primary Immunodeficiency Diseases (PID), sponsored by Baxalta now part of Shire. Completed at 11 sites in United States. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2021-05-19.
Sponsored by Baxalta now part of Shire (part of Takeda) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Primary Immunodeficiency Diseases by Takeda — 2 open to participants now, 3 under way, 1 of them phase 3. Primary Immunodeficiency Diseases · Takeda.
Among the 23 studies in Primary Immunodeficiency Diseases by Takeda, this one is the 3rd largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2010, is one of 9 in phase 3, and was the 6th registered.
211 studies on the registry are indexed under Primary Immunodeficiency Diseases; 51 are open to participants now.
Browse Primary Immunodeficiency Diseases studies →2 of the 23 studies in Primary Immunodeficiency Diseases by Takeda are open now, in 1 country. Recruiting first, the newest first:
Takeda · Sites in Japan
Takeda
Ages 6+
By country, each count listing its studies:
Of the 35 Primary Immunodeficiency Diseases studies recruiting now, 12 (34%) set no upper age limit and 10 (29%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.
This study: 2 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 14 · Phase 4 2
First in 2002; this study’s year is marked. 1 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 66 is above the median of 36 across 125 interventional studies indexed under Primary Immunodeficiency Diseases.
Median enrollment 47 across the 18 interventional studies, 113 across the 4 observational. Of the 19 that completed or were terminated, 12 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Baxalta now part of Shire, one of the names counted as Takeda. Under that name alone:
Baxalta now part of Shire is the lead sponsor of 111 studies on the registry; none are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 23 studies in Primary Immunodeficiency Diseases by Takeda, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The original purpose of the study is to assess the long-term safety, tolerability, and practicability of the subcutaneous (SC) treatment with Immune Globulin Subcutaneous Solution (IGSC), 10% facilitated with recombinant human hyaluronidase (rHuPH20) in participants with Primary Immunodeficiency Diseases (PID) who have completed Baxter Clinical Study Protocol No. 160603.
Following a discussion with the FDA, all participants still active in the study stopped treatment with rHuPH20 to assure safety of the participants participating in the study and went into a safety follow-up.
During this safety follow-up period, participants underwent either intravenous (IV) or SC treatment with IGSC, 10%. The IV or SC administration route was at the discretion of the participant and the investigator.
IGSC, 10% is the same product as IMMUNE GLOBULIN INTRAVENOUS (HUMAN), 10% (IGIV, 10%) quoted in study 160603.
IGSC, 10% is abbreviated to IGI, 10% [IMMUNE GLOBULIN INFUSION (HUMAN), 10%]
In the US the product is licensed (trade name GAMMAGARD LIQUID) for the intravenous (IV) and SC replacement therapy of antibody deficiency in patients with PID.
In the EU this product is licensed (trade name KIOVIG)
IGSC, 10% with rHuPH20 established name is Innume Glubulin Infusion 10% (Human) with Recombinant Human Hyualuronidase.
US trade name is HYQVIA EU trade name is HyQvia
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Efficacy and safety of subcutaneous (SC) administration of Immune Globulin Subcutaneous Solution (IGSC), 10% after SC administration of recombinant human hyaluronidase (rHuPH20) followed by Safety of SC of IGSC, 10% only (safety follow-up)
Biological: SC treatment with IGSC, 10% with rHuPH20 followed by SC/IGSC, 10% only (safety)
Efficacy and safety of subcutaneous (SC) administration of Immune Globulin Subcutaneous Solution (IGSC), 10% after SC administration of recombinant human hyaluronidase (rHuPH20) followed by Safety of intravenous (IV) administration of IGSC, 10% only (safety follow-up)
Biological: SC treatment with IGSC, 10% with rHuPH20 followed by IV/IGSC, 10% only (safety)
Partial efficacy (trough levels of immunoglobulin G \[IgG\] only) and safety of intravenous (IV) administration of IGSC, 10% only. This was for participants enrolled in the study who had anti-rHuPH20 andibody titer from study160603
Biological: IV treatment with IGSC, 10%
Participants are to continue on the same doses and treatment intervals of IGSC, 10% adjusted for body weight, and rHuPH20 that were used for the last infusions in Study epoch 2 of Study 160603 (NCT00814320). After 3 infusions, participants are to change treatment to a 2-week interval, if agreed with participant and investigator. During this safety follow-up period, participants are treated with IGSC, 10% via the SC route. Treatment occurred once every week. The dose was the weekly equivalent of the most recent IV dose (adjusted per body weight) and multiplied by 1.37.
Also known as: HYQVIA (IGSC, 10% with rHuPH20 [US]), 10% with rHuPH20 [EU]), GAMMAGARD LIQUID (IGSC, 10% [US]), KIOVIG (IGSC, 10% [EU])
Participants are to continue on the same doses and treatment intervals of IGSC, 10% adjusted for body weight, and rHuPH20 that were used for the last infusions in Study epoch 2 of Study 160603 (NCT00814320). After 3 infusions, participants are to change treatment to a 2-week interval, if agreed with participant and investigator. During this safety follow-up period, participants are treated with IGSC, 10% via the intravenous (IV) route. Treatment occurred once every 3-4 weeks. The weekly dose equivalent was 100% of the most recent IV dose.
Also known as: GAMMAGARD LIQUID (IGSC, 10% [US]), KIOVIG (IGSC, 10% [EU]), HyQvia (IGSC, 10% with rHuPH20 [EU]), 10% with rHuPH20 [US])
During this safety follow-up period, participants are treated with IGSC, 10% via the intravenous (IV) route.
Also known as: GAMMAGARD LIQUID (US), KIOVIG (EU)
Annual Rate of Serious Bacterial Infections
The point estimate of the annual rate of validated acute serious bacterial infections (VASBIs) per participant per year was provided during subcutaneous (SC) administration of Immune Globulin Subcutaneous Solution (IGSC), 10%, after SC administration of human recombinant hyaluronidase (rHuPH20). This efficacy outcome measure was only applicable prior to the safety follow-up i.e. before discontinuation of rHuPH20.
Time frame: Throughout the efficacy period only (from 60 to 729 days)
Annual Rate of All Infections
Annualized rate of infections per participant as defined by MedDRA system organ class (SOC) "infections and infestations". The point estimate of the annual rate of all infections was provided during subcutaneous (SC) administration of Immune Globulin Subcutaneous Solution (IGSC), 10%, after SC administration of human recombinant hyaluronidase (rHuPH20). This efficacy outcome measure was only applicable prior to the safety follow-up i.e. before discontinuation of rHuPH20.
Time frame: Throughout the efficacy period only (from 60 to 729 days)
Trough Levels of IgG Maintained During the Study Period in Relation to Dose Frequency
Immunoglobulin (IgG) steady state trough levels were measured in relation to dose frequency by measuring in relation to treatment interval (2-, 3- or 4-week intervals). Initially participants were administered subcutaneous (SC) infusions of Immune Globulin Subcutaneous Solution (IGSC), 10%, after SC administration of human recombinant hyaluronidase (rHuPH20) \[or IV infusions of IGSC, 10% only\] at the treatment intervals and dose determined by epoch 2 of study 160603 (3- or 4-week intervals). After 3 treatment intervals (either 3- or 4- week intervals), participants changed to a 2-week treatment interval, if agreed with participant and investigator, with the dose adjusted to 1/2 of the 4-week dose or 2/3 of the 3-week dose, whichever was applicable. The rHuPH20 dose was adjusted relative to the new IGSC, 10% dose in order to achieve a dose ratio of 75 U/g IgG. This efficacy outcome measure was only applicable prior to the safety follow-up i.e. before discontinuation of rHuPH20.
Time frame: Throughout the efficacy period only (from 60 to 729 days)
The Annual Rate of Serious Adverse Events (SAEs), Related and Not Related to Study Drugs
Separated into age groups as described below and into related (related to either study drug) and not related (not related to either or both study drugs). Study drugs are Immune Globulin Subcutaneous Solution (IGSC), 10% and recombinant human hyaluronidase (rHuPH20).
Time frame: Throughout entire study period (up to 3 years). Duration of participation for each participant is variable depending on date of enrollment and their anti-rHuPH20 binding antibody titer.
Percentage of Infusions for Which the Infusion Rate Was Reduced and/or the Infusion Interrupted or Stopped for Tolerability Concerns or for AEs
Time frame: Throughout entire study period (up to 3 years). Duration of participation for each participant is variable depending on date of enrollment and their anti-rHuPH20 binding antibody titer.
Percentage of Infusions Associated With One or More Moderate or Severe AEs (Including and Excluding Infections) That Begin During or Within 72 Hours of Completion of an Infusion
Time frame: Throughout entire study period (up to 3 years). Duration of participation for each participant is variable depending on date of enrollment and their anti-rHuPH20 binding antibody titer.
Number of Participants Who Develop Antibodies and Neutralizing Antibodies to rHuPH20
Participants who develop binding antibodies and/or neutralizing antibodies to recombinant human hyaluronidase (rHuPH20) from study 160603 and/ or from this study (160902) are included here. This study (160902) is an extension of study 160603. Study 160603 was divided into 2 study epochs. In epoch 1 of study 160603 participants were treated with intravenous (IV) administration of Immune Globulin Subcutaneous Solution (IGSC), 10%. In epoch 2 of study 160603 participants were treated with subcutaneous (SC) administration of IGSC, 10% after SC administration of rHuPH20. Only participants who completed study 160603 were eligible to be screened and enrolled in this study (160902). In this study, participants started on same doses of IGSC, 10% and rHuPH20 that were used for the last infusions in epoch 2 of study 160603.
Time frame: Throughout entire study period for 160603 (1 year 11 months) and 160902 (2 years 11 months)
Percentage of Participants Who Develop Antibodies and Neutralizing Antibodies to rHuPH20
Participants who develop binding antibodies and/or neutralizing antibodies to recombinant human hyaluronidase (rHuPH20) from study 160603 and/ or from this study (160902) are included here. This study (160902) is an extension of study 160603. Study 160603 was divided into 2 study epochs. In epoch 1 of study 160603 participants were treated with intravenous (IV) administration of Immune Globulin Subcutaneous Solution (IGSC), 10%. In epoch 2 of study 160603 participants were treated with subcutaneous (SC) administration of IGSC, 10% after SC administration of rHuPH20. Only participants who completed study 160603 were eligible to be screened and enrolled in this study (160902). In this study, participants started on same doses of IGSC, 10% and rHuPH20 that were used for the last infusions in epoch 2 of study 160603.
Time frame: Throughout entire study period for 160603 (1 year 11 months) and 160902 (2 years 11 months)
Number of Participants With AEs Related to Anti-rHuPH20 Titers
Time frame: Throughout entire study period for 160603 (1 year 11 months) and 160902 (2 years 11 months)
Percentage of Participants With AEs Related to Anti-rHuPH20 Titers
Time frame: Throughout entire study period for 160603 (1 year 11 months) and 160902 (2 years 11 months)
Number of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Relatedness to the Study Drug, and Severity (A-F).
Categories presented as Preferred Term-Seriousness-Relatedness-Severity. The following codes are to be used: Seriousness: non-SAE-non-serious AE; SAE-serious AE Relatedness to study drug: R (related to either study drug); NR (not related to either or both study drugs). Study drugs are Immune Globulin Subcutaneous Solution, 10% (IGSC, 10%) and recombinant human hyaluronidase (rHuPH20) Severity: Mild; Mod (Moderate); Severe Preferred terms abbreviated: ADHD - Attention Deficit/Hyperactivity Disorder COPD - Chronic Obstructive Pulmonary Disease Other abbreviations: CPK - Creatinine Phosphokinase Inc. - Increased Dis - Disease Sml- small
Time frame: Throughout entire study period (up to 3 years). Duration of participation for each participant is variable depending on date of enrollment and their anti-rHuPH20 binding antibody titer.
Number of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Relatedness to the Study Drug, and Severity (G-M).
Categories presented as Preferred Term-Seriousness-Relatedness-Severity. The following codes are to be used: Seriousness: non-SAE-non-serious AE; SAE-serious AE Relatedness to study drug: R (related to either study drug); NR (not related to either or both study drugs). Study drugs are Immune Globulin Subcutaneous Solution, 10% (IGSC, 10%) and recombinant human hyaluronidase (rHuPH20) Severity: Mild; Mod (Moderate); Severe
Time frame: Throughout entire study period (up to 3 years). Duration of participation for each participant is variable depending on date of enrollment and their anti-rHuPH20 binding antibody titer.
Number of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Relatedness to the Study Drug, and Severity (N-Z).
Categories presented as Preferred Term-Seriousness, Relatedness, Severity. The following codes are to be used: Seriousness: non-SAE-non-serious AE; SAE-serious AE Relatedness to study drug: R (related to either study drug); NR (not related to either or both study drugs). Study drugs are Immune Globulin Subcutaneous Solution, 10% (IGSC, 10%) and recombinant human hyaluronidase (rHuPH20) Severity: Mild; Mod (Moderate); Severe Preferred terms abbreviated: Infection - Inf.
Time frame: Throughout entire study period (up to 3 years). Duration of participation for each participant is variable depending on date of enrollment and their anti-rHuPH20 binding antibody titer.
Rate of All AEs Per Participant Categorized by MedDRA Preferred Terms, Seriousness and Severity (A-F).
Categories presented as Preferred Term-Seriousness-Severity. The following codes are to be used: Seriousness: non-SAE-non-serious AE; SAE-serious AE Severity: Mild; Mod (Moderate); Sev (Severe) Preferred terms abbreviated: ADHD - Attention Deficit/Hyperactivity Disorder COPD - Chronic Obstructive Pulmonary Disease Other abbreviations: Inc. - Increased Dis. - Disease
Time frame: Throughout entire study period (up to 3 years). Duration of participation for each participant is variable depending on date of enrollment and their anti-rHuPH20 binding antibody titer.
Rate of All AEs Per Participant Categorized by MedDRA Preferred Terms, Seriousness and Severity (G-M).
Categories presented as Preferred term-Seriousness-Severity. The following codes are to be used: Seriousness: non-SAE-non-serious AE; SAE-serious AE Severity: Mild; Mod (Moderate); Sev (Severe)
Time frame: Throughout entire study period (up to 3 years). Duration of participation for each participant is variable depending on date of enrollment and their anti-rHuPH20 binding antibody titer.
Rate of All AEs Per Participant Categorized by MedDRA Preferred Terms, Seriousness and Severity (N-Z).
Categories presented as Preferred term-Seriousness-Severity. The following codes are to be used: Seriousness: non-SAE-non-serious AE; SAE-serious AE Severity: Mild; Mod (Moderate); Sev (Severe)
Time frame: Throughout entire study period (up to 3 years). Duration of participation for each participant is variable depending on date of enrollment and their anti-rHuPH20 binding antibody titer.
Rate of All AEs Per Infusion Categorized by MedDRA Preferred Terms, Seriousness and Severity (A-F).
Categories presented as Preferred term-Seriousness-Severity. The following codes are to be used: Seriousness: non-SAE-non-serious adverse event; SAE- serious adverse event Severity: Mild; Mod (Moderate); Sev (Severe) Preferred terms abbreviated: ADHD - Attention Deficit/Hyperactivity Disorder COPD - Chronic Obstructive Pulmonary Disease Other abbreviations: Inc. - Increased Dis. - Disease
Time frame: Throughout entire study period (up to 3 years). Duration of participation for each participant is variable depending on date of enrollment and their anti-rHuPH20 binding antibody titer.
Rate of All AEs Per Infusion Categorized by MedDRA Preferred Terms, Seriousness and Severity (G-M).
Categories presented as Preferred term-Seriousness-Severity. The following codes are to be used: Seriousness: non-SAE-non-serious AE; SAE-serious AE Severity: Mild; Mod (Moderate); Sev (Severe)
Time frame: Throughout entire study period (up to 3 years). Duration of participation for each participant is variable depending on date of enrollment and their anti-rHuPH20 binding antibody titer.
Rate of All AEs Per Infusion Categorized by MedDRA Preferred Terms, Seriousness and Severity (N-Z).
Categories presented as Preferred term-Seriousness-Severity. The following codes are to be used: Seriousness: non-SAE-non-serious AE; SAE-serious AE Severity: Mild; Mod (Moderate); Sev (Severe)
Time frame: Throughout entire study period (up to 3 years). Duration of participation for each participant is variable depending on date of enrollment and their anti-rHuPH20 binding antibody titer.
Rate of AEs Per Participant (Including and Excluding Infections) Determined by the Investigator to be Related to the Study Drug That Occur at Any Time During the Study ("Related")
Categories presented as adverse event (AE) type : Total, Local, Systemic including infections, Systemic excluding infections, and Severity (Mild, Moderate, Severe, Total). All of these adverse events are non-serious AEs.
Time frame: Throughout entire study period (up to 3 years). Duration of participation for each participant is variable depending on date of enrollment and their anti-rHuPH20 binding antibody titer.
Rate of AEs Per Infusion (Including and Excluding Infections) Determined by the Investigator to be Related to the Study Drug That Occur at Any Time During the Study ("Related")
Categories presented as adverse event (AE) type : Total, Local, Systemic including infections, Systemic excluding infections, and Severity (Mild, Moderate, Severe, Total). All of these adverse events are non-serious AEs.
Time frame: Throughout entire study period (up to 3 years). Duration of participation for each participant is variable depending on date of enrollment and their anti-rHuPH20 binding antibody titer.
Rate of AEs Per Participant (Including and Excluding Infections) Temporarily Associated With the Infusion
Categories presented as adverse event (AE) type : Total, Local, Systemic including infections, Systemic excluding infections, Seriousness: Serious AE (SAE), non-serious AE (nsAE) and Severity (Mild, Moderate, Severe, Total). All of these adverse events are non-serious AEs.
Time frame: Throughout entire study period (up to 3 years). Duration of participation for each participant is variable depending on date of enrollment and their anti-rHuPH20 binding antibody titer.
Rate of AEs Per Infusion (Including and Excluding Infections) Temporarily Associated With the Infusion
Categories presented as adverse event (AE) type : Total, Local, Systemic including infections, Systemic excluding infections, Seriousness: Serious AE (SAE), non-serious AE (non-SAE) and Severity (Mild, Moderate, Severe, Total). All of these adverse events are non-serious AEs.
Time frame: Throughout entire study period (up to 3 years). Duration of participation for each participant is variable depending on date of enrollment and their anti-rHuPH20 binding antibody titer.
Percentage of Infusions Associated With One or More Local AEs (Including and Excluding Infections), at Any Time During the Study
Time frame: Throughout entire study period (up to 3 years). Duration of participation for each participant is variable depending on date of enrollment and their anti-rHuPH20 binding antibody titer.
Recruitment was conducted 11 clinical sites in the United States.
| Milestone | IGSC - rHuPH20 Then IGSC, 10% or IGIV, 10% Only | IGIV, 10% Only |
|---|---|---|
| Started | 63 | 3 |
| Completed | 48 | 3 |
| Not completed | 15 | 0 |
| Withdrew: Withdrawal by subject | 4 | 0 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Bone marrow transplant | 1 | 0 |
| Withdrew: Clinical site closed by sponsor | 6 | 0 |
| Withdrew: Site elected to exit study | 3 | 0 |
| Milestone | IGSC - rHuPH20 Then IGSC, 10% or IGIV, 10% Only | IGIV, 10% Only |
|---|---|---|
| Started | 48 | 3 |
| Completed | 47 | 3 |
| Not completed | 1 | 0 |
| Withdrew: Adverse event | 1 | 0 |
The point estimate of the annual rate of validated acute serious bacterial infections (VASBIs) per participant per year was provided during subcutaneous (SC) administration of Immune Globulin Subcutaneous Solution (IGSC), 10%, after SC administration of human recombinant hyaluronidase (rHuPH20). This efficacy outcome measure was only applicable prior to the safety follow-up i.e. before discontinuation of rHuPH20.
| Estimated infections/year | All Participants Treated With IGSC, 10% and rHuPH20 |
|---|---|
| Annual Rate of Serious Bacterial Infections | 0.020 |
Annualized rate of infections per participant as defined by MedDRA system organ class (SOC) "infections and infestations". The point estimate of the annual rate of all infections was provided during subcutaneous (SC) administration of Immune Globulin Subcutaneous Solution (IGSC), 10%, after SC administration of human recombinant hyaluronidase (rHuPH20). This efficacy outcome measure was only applicable prior to the safety follow-up i.e. before discontinuation of rHuPH20.
| Number of infections/year | All Participants Treated With IGSC, 10% and rHuPH20 |
|---|---|
| Annual Rate of All Infections | 2.86 (2.36 to 3.43) |
Immunoglobulin (IgG) steady state trough levels were measured in relation to dose frequency by measuring in relation to treatment interval (2-, 3- or 4-week intervals). Initially participants were administered subcutaneous (SC) infusions of Immune Globulin Subcutaneous Solution (IGSC), 10%, after SC administration of human recombinant hyaluronidase (rHuPH20) \[or IV infusions of IGSC, 10% only\] at the treatment intervals and dose determined by epoch 2 of study 160603 (3- or 4-week intervals). After 3 treatment intervals (either 3- or 4- week intervals), participants changed to a 2-week treatment interval, if agreed with participant and investigator, with the dose adjusted to 1/2 of the 4-week dose or 2/3 of the 3-week dose, whichever was applicable. The rHuPH20 dose was adjusted relative to the new IGSC, 10% dose in order to achieve a dose ratio of 75 U/g IgG. This efficacy outcome measure was only applicable prior to the safety follow-up i.e. before discontinuation of rHuPH20.
| g/L | All Participants Treated With rHuPH20 and/or IGSC, 10% |
|---|---|
| 2-Week Treatment Interval [N=17] | 10.900 (9.390 to 13.300) |
| 3-Week Treatment Interval [N=9] | 12.300 (11.500 to 15.300) |
| 4-Week Treatment Interval [N=47] | 9.760 (9.260 to 10.700) |
Separated into age groups as described below and into related (related to either study drug) and not related (not related to either or both study drugs). Study drugs are Immune Globulin Subcutaneous Solution (IGSC), 10% and recombinant human hyaluronidase (rHuPH20).
| SAEs/year | IGSC, 10% - rHuPH20 | Safety Follow-up - IGSC, 10% or IGIV, 10% Only |
|---|---|---|
| Participants aged 2 to <12 years - not related | 0.0000 | 0.0000 |
| Participants aged 2 to <12 years - related | 0.0000 | 0.0000 |
| Participants aged 12 to <16 years - not related | 0.0768 | 0.0000 |
| Participants aged 12 to <16 years - related | 0.0000 | 0.0000 |
| Participants aged 16 to <65 years - not related | 0.0950 | 0.0449 |
| Participants aged 16 to <65 years - related | 0.0000 | 0.0000 |
| Participants aged 65 years and older- not related | 0.5737 | 0.4728 |
| Participants aged 65 years and older- related | 0.0000 | 0.0000 |
| Percentage of infusions | IGSC, 10% - rHuPH20 | Safety Follow-up - IGSC, 10% or IGIV, 10% Only |
|---|---|---|
| Percentage of infusion rates reduced | 1.3 | 0.3 |
| Percentage of infusions interrupted | 0.8 | 0.2 |
| Percentage of infusions stopped | 0.1 | 0.2 |
| Percentage of infusions | IGSC, 10% - rHuPH20 | Safety Follow-up - IGSC, 10% or IGIV, 10% Only |
|---|---|---|
| Including Infections | 3.4 | 4.7 |
| Excluding Infections | 2.9 | 4.0 |
Participants who develop binding antibodies and/or neutralizing antibodies to recombinant human hyaluronidase (rHuPH20) from study 160603 and/ or from this study (160902) are included here. This study (160902) is an extension of study 160603. Study 160603 was divided into 2 study epochs. In epoch 1 of study 160603 participants were treated with intravenous (IV) administration of Immune Globulin Subcutaneous Solution (IGSC), 10%. In epoch 2 of study 160603 participants were treated with subcutaneous (SC) administration of IGSC, 10% after SC administration of rHuPH20. Only participants who completed study 160603 were eligible to be screened and enrolled in this study (160902). In this study, participants started on same doses of IGSC, 10% and rHuPH20 that were used for the last infusions in epoch 2 of study 160603.
| Number of participants | All Participants Treated With rHuPH20 |
|---|---|
| Binding antibodies (>=1:160) | 13 |
| Neutralizing antibodies | 0 |
Participants who develop binding antibodies and/or neutralizing antibodies to recombinant human hyaluronidase (rHuPH20) from study 160603 and/ or from this study (160902) are included here. This study (160902) is an extension of study 160603. Study 160603 was divided into 2 study epochs. In epoch 1 of study 160603 participants were treated with intravenous (IV) administration of Immune Globulin Subcutaneous Solution (IGSC), 10%. In epoch 2 of study 160603 participants were treated with subcutaneous (SC) administration of IGSC, 10% after SC administration of rHuPH20. Only participants who completed study 160603 were eligible to be screened and enrolled in this study (160902). In this study, participants started on same doses of IGSC, 10% and rHuPH20 that were used for the last infusions in epoch 2 of study 160603.
| Percentage of participants | All Participants Treated With rHuPH20 |
|---|---|
| Binding antibodies (>=1:160) | 19.7 |
| Neutralizing antibodies | 0 |
| Number of participants | All Participants Treated With rHuPH20 |
|---|---|
| Number of Participants With AEs Related to Anti-rHuPH20 Titers | 12 |
| Percentage of participants | All Participants Treated With rHuPH20 |
|---|---|
| Percentage of Participants With AEs Related to Anti-rHuPH20 Titers | 92.3 |
Categories presented as Preferred Term-Seriousness-Relatedness-Severity. The following codes are to be used: Seriousness: non-SAE-non-serious AE; SAE-serious AE Relatedness to study drug: R (related to either study drug); NR (not related to either or both study drugs). Study drugs are Immune Globulin Subcutaneous Solution, 10% (IGSC, 10%) and recombinant human hyaluronidase (rHuPH20) Severity: Mild; Mod (Moderate); Severe Preferred terms abbreviated: ADHD - Attention Deficit/Hyperactivity Disorder COPD - Chronic Obstructive Pulmonary Disease Other abbreviations: CPK - Creatinine Phosphokinase Inc. - Increased Dis - Disease Sml- small
| Number of AEs | IGSC, 10% - rHuPH20 | Safety Follow-up - IGSC, 10% or IGIV, 10% Only |
|---|---|---|
| Abdominal Distension-non-SAE-R-Mild | 6 | 0 |
| Abdominal Hernia-non-SAE-NR-Mild | 1 | 0 |
| Abdominal Mass-non-SAE-NR-Mild | 0 | 1 |
| Abdominal Pain-non-SAE-NR-Mild | 2 | 1 |
| Abdominal Pain-non-SAE-NR-Mod | 4 | 0 |
| Abdominal Pain-non-SAE-NR-Severe | 1 | 0 |
| Abdominal Pain-non-SAE-R-Mild | 0 | 3 |
| Abdominal Pain Upper-non-SAE-NR-Mild | 7 | 0 |
| Abdominal Pain Upper-non-SAE-R-Mild | 1 | 0 |
| Abdominal Tenderness-non-SAE-NR-Mild | 2 | 0 |
| Abdominal Tenderness-non-SAE-R-Mild | 1 | 0 |
| Abnormal Loss Of Weight-non-SAE-NR-Mild | 1 | 0 |
| Acarodermatitis-non-SAE-NR-Mild | 2 | 1 |
| Acarodermatitis-non-SAE-NR-Mod | 2 | 0 |
| Acne-non-SAE-NR-Mild | 1 | 0 |
| Acne-non-SAE-NR-Mod | 1 | 0 |
| Actinic Keratosis-non-SAE-NR-Mild | 1 | 0 |
| Actinic Keratosis-non-SAE-NR-Mod | 1 | 2 |
| Activities of Daily Living Impaired-non-SAE-NR-Mod | 1 | 0 |
| Acute Sinusitis-non-SAE-NR-Mild | 0 | 1 |
| Acute Sinusitis-non-SAE-NR-Mod | 1 | 0 |
| Acute Stress Disorder-non-SAE-NR-Mild | 1 | 0 |
| Adhesiolysis-SAE-NR-Mod | 1 | 0 |
| Age Related Macular Degeneration-non-SAE-NR-Mild | 1 | 0 |
| Agitation-non-SAE-NR-Mild | 1 | 0 |
| Aldolase Increased-non-SAE-NR-Mild | 1 | 0 |
| Anaphylactic Reaction-non-SAE-R-Sev | 0 | 1 |
| Animal Bite-non-SAE-NR-Mild | 1 | 0 |
| Animal Scratch-non-SAE-NR-Mild | 0 | 1 |
| Anxiety-non-SAE-NR-Mild | 2 | 0 |
| Anxiety-non-SAE-NR-Mod | 2 | 0 |
| Aortic Calcification-non-SAE-NR-Mild | 1 | 0 |
| Aortic Stenosis-non-SAE-NR-Mild | 1 | 0 |
| Aortic Stenosis-non-SAE-NR-Mod | 1 | 0 |
| Aortic Valve Incompetence-non-SAE-NR-Mod | 1 | 0 |
| Aortic Valve Incompetence-SAE-NR-Sev | 1 | 0 |
| Apthous Stomatitis-non-SAE-NR-Mild | 4 | 2 |
| Apthous Stomatitis-non-SAE-NR-Mod | 2 | 0 |
| Apthous Stomatitis-non-SAE-R-Mild | 1 | 0 |
| Appendicitis-SAE-NR-Mod | 1 | 0 |
| Application Site Erythema-non-SAE-NR-Mild | 1 | 0 |
| Arteritis-non-SAE-NR-Mod | 1 | 0 |
| Arthralgia-non-SAE-NR-Mild | 7 | 1 |
| Arthralgia-non-SAE-NR-Mod | 0 | 6 |
| Arthralgia-non-SAE-R-Mild | 1 | 0 |
| Arthropod Bite-non-SAE-NR-Mild | 1 | 1 |
| Asthenia-non-SAE-NR-Mild | 1 | 0 |
| Asthenia-non-SAE-NR-Mod | 2 | 0 |
| Asthenia-non-SAE-R-Mild | 6 | 0 |
| Asthenia-non-SAE-R-Mod | 7 | 1 |
| Asthma-non-SAE-NR-Mild | 12 | 3 |
| Asthma-non-SAE-NR-Mod | 20 | 3 |
| Ataxia-non-SAE-NR-Mild | 2 | 0 |
| Atelectasis-non-SAE-NR-Mild | 1 | 0 |
| Atrial Fibrillation-non-SAE-NR-Mild | 1 | 0 |
| Atrial Fibrillation-SAE-NR-Mod | 1 | 0 |
| ADHD-non-SAE-NR-Mod | 1 | 0 |
| Back Pain-non-SAE-NR-Mild | 3 | 2 |
| Back Pain-non-SAE-NR-Mod | 3 | 2 |
| Back Pain-non-SAE-R-Sev | 0 | 1 |
| Basal Cell Carcinoma-non-SAE-NR-Mild | 1 | 0 |
| Basal Cell Carcinoma-non-SAE-NR-Mod | 4 | 1 |
| Blepharochalasis-non-SAE-NR-Mild | 1 | 0 |
| Blister-non-SAE-NR-Mild | 1 | 0 |
| Blood Bicarbonate Decreased-non-SAE-NR-Mild | 1 | 0 |
| Blood CPK Increased-non-SAE-NR-Mild | 3 | 0 |
| Blood CPK Increased-non-SAE-NR-Mod | 2 | 0 |
| Blood Creatinine Increased-non-SAE-NR-Mild | 1 | 0 |
| Blood Creatinine Increased-non-SAE-R-Mild | 0 | 1 |
| Blood Glucose Increased-non-SAE-NR-Mild | 4 | 1 |
| Blood Urea Increased-non-SAE-R-Mild | 0 | 1 |
| Blood Urine Present-non-SAE-NR-Mild | 2 | 0 |
| Body Tinea-non-SAE-NR-Mild | 2 | 0 |
| Bone Pain-non-SAE-NR-Mild | 1 | 0 |
| Breast Calcifications-non-SAE-NR-Mild | 1 | 0 |
| Breast Dysplasia-non-SAE-NR-Mild | 0 | 1 |
| Bronchiolitis-non-SAE-NR-Mild | 1 | 0 |
| Bronchitis-non-SAE-NR-Mild | 11 | 5 |
| Bronchitis-non-SAE-NR-Mod | 11 | 2 |
| Burns Second Degree-non-SAE-NR-Mild | 1 | 0 |
| Bursitis-non-SAE-NR-Mild | 2 | 0 |
| Candidiasis-non-SAE-NR-Mild | 1 | 0 |
| Cardiac Failure Congestive-SAE-NR-Mild | 1 | 0 |
| Cardiac Murmur-non-SAE-NR-Mod | 2 | 0 |
| Cardiomegaly-non-SAE-NR-Mild | 0 | 1 |
| Cardiomegaly-non-SAE-NR-Mod | 2 | 0 |
| Cardiomyopathy-non-SAE-NR-Mild | 1 | 0 |
| Cataract-non-SAE-NR-Mild | 1 | 1 |
| Cataract-non-SAE-NR-Mod | 2 | 0 |
| Cellulitis-non-SAE-NR-Mild | 2 | 0 |
| Cellulitis-non-SAE-NR-Mod | 2 | 1 |
| Cellulitis-SAE-NR-Mod | 0 | 1 |
| Cellulitis Male Ext. Genital Organ-non-SAE-NR-Mod | 1 | 0 |
| Cerebral Sml Vessel Ischaemic Dis-non-SAE-NR-Mild | 1 | 0 |
| Cerumen Impaction-non-SAE-NR-Mild | 2 | 2 |
| Cervical Spinal Stenosis-non-SAE-NR-Mild | 0 | 1 |
| Chapped Lips-non-SAE-NR-Mild | 1 | 0 |
| Cheilitis-non-SAE-NR-Mild | 1 | 0 |
| Chest Discomfort-non-SAE-NR-Mild | 1 | 0 |
| Chest Pain-non-SAE-NR-Mild | 2 | 0 |
| Chest Pain-non-SAE-NR-Mod | 1 | 0 |
| Chills-non-SAE-NR-Mild | 2 | 0 |
| Chills-non-SAE-NR-Mod | 1 | 0 |
| Chills-non-SAE-R-Mild | 11 | 1 |
| Cholelithiasis-non-SAE-NR-Mild | 2 | 0 |
| Chondromalacia-non-SAE-NR-Mod | 1 | 0 |
| Chromaturia-non-SAE-NR-Mild | 1 | 0 |
| COPD-non-SAE-NR-Mild | 2 | 0 |
| COPD-non-SAE-NR-Mod | 3 | 0 |
| COPD-SAE-NR-Mod | 1 | 0 |
| COPD-SAE-NR-Sev | 1 | 0 |
| Chronic Sinusitis-non-SAE-NR-Mild | 5 | 2 |
| Chronic Sinusitis-non-SAE-NR-Mod | 3 | 1 |
| Conjunctival Haemorrhage-non-SAE-NR-Mild | 1 | 0 |
| Conjunctival Hyperaemia-non-SAE-NR-Mild | 2 | 0 |
| Conjunctivitis-non-SAE-NR-Mild | 0 | 2 |
| Conjunctivitis Allergic-non-SAE-NR-Mild | 1 | 1 |
| Conjunctivitis Allergic-non-SAE-NR-Mod | 0 | 2 |
| Conjunctivitis Infective-non-SAE-NR-Mild | 3 | 1 |
| Constipation-non-SAE-NR-Mild | 3 | 3 |
| Constipation-non-SAE-NR-Mod | 3 | 0 |
| Contusion-non-SAE-NR-Mild | 0 | 3 |
| Convulsion-non-SAE-NR-Mild | 1 | 0 |
| Convulsion-non-SAE-NR-Mod | 2 | 1 |
| Coombs Direct Test Positive-non-SAE-R-Mild | 1 | 0 |
| Coombs Test Positive-non-SAE-NR-Mild | 1 | 0 |
| Coombs Test Positive-non-SAE-R-Mild | 1 | 0 |
| Corneal Abrasion-non-SAE-NR-Mild | 1 | 0 |
| Costochondritis-non-SAE-NR-Mild | 1 | 0 |
| Costochondritis-non-SAE-NR-Sev | 1 | 0 |
| Cough-non-SAE-NR-Mild | 10 | 3 |
| Cough-non-SAE-NR-Mod | 3 | 1 |
| Cough-non-SAE-R-Mild | 1 | 0 |
| Cryptosporidiosis Infection-SAE-NR-Sev | 1 | 0 |
| Cyst-non-SAE-NR-Mild | 1 | 0 |
| Cyst-non-SAE-NR-Mod | 2 | 0 |
| Cystitis-non-SAE-NR-Mild | 1 | 0 |
| Cystocele-SAE-NR-Mod | 1 | 0 |
| Decreased Appetite-non-SAE-NR-Mild | 1 | 0 |
| Decreased Appetite-non-SAE-NR-Mod | 2 | 0 |
| Decreased Appetite-non-SAE-R-Mild | 3 | 8 |
| Dehydration-non-SAE-NR-Mild | 1 | 0 |
| Dehydration-non-SAE-NR-Mod | 1 | 0 |
| Dental Caries-non-SAE-NR-Mod | 2 | 0 |
| Depression-non-SAE-NR-Mild | 1 | 0 |
| Depression-non-SAE-NR-Mod | 3 | 1 |
| Dermal Cyst-non-SAE-NR-Mod | 1 | 0 |
| Dermatitis-non-SAE-NR-Mild | 1 | 0 |
| Dermatitis Allergic-non-SAE-NR-Mild | 0 | 1 |
| Dermatitis Atopic-non-SAE-NR-Mild | 1 | 0 |
| Dermatitis Contact-non-SAE-NR-Mild | 3 | 0 |
| Dermatitis Contact-non-SAE-NR-Mod | 1 | 0 |
| Dermatitis Psoriasiform-non-SAE-NR-Sev | 1 | 0 |
| Device Breakage-non-SAE-NR-Mod | 1 | 0 |
| Device Failure-non-SAE-NR-Mod | 1 | 0 |
| Diarrhoea-non-SAE-NR-Mild | 15 | 4 |
| Diarrhoea-non-SAE-NR-Mod | 2 | 0 |
| Diarrhoea-non-SAE-R-Mild | 2 | 1 |
| Dizziness-non-SAE-NR-Mild | 5 | 1 |
| Dizziness-non-SAE-R-Mild | 5 | 0 |
| Dizziness-non-SAE-R-Mod | 1 | 0 |
| Drug Eruption-non-SAE-NR-Mod | 1 | 0 |
| Drug Hypersensitivity-non-SAE-NR-Mild | 3 | 0 |
| Dry Eye-non-SAE-NR-Mild | 1 | 0 |
| Dry Eye-non-SAE-NR-Mod | 1 | 1 |
| Dry Mouth-non-SAE-NR-Mild | 0 | 1 |
| Dry Skin-non-SAE-NR-Mild | 0 | 1 |
| Dysmenorrhoea-non-SAE-NR-Mild | 1 | 0 |
| Dyspepsia-non-SAE-NR-Mild | 0 | 3 |
| Dysplastic Naevus-non-SAE-NR-Mod | 1 | 0 |
| Dyspnoea-non-SAE-NR-Mild | 2 | 1 |
| Dyspnoea-non-SAE-NR-Mod | 2 | 0 |
| Dysuria-non-SAE-NR-Mild | 1 | 1 |
| Dysuria-non-SAE-NR-Mod | 2 | 0 |
| Ear Infection-non-SAE-NR-Mild | 1 | 0 |
| Ear Infection-non-SAE-NR-Mod | 3 | 0 |
| Ear Pain-non-SAE-NR-Mild | 1 | 0 |
| Ear Pain-non-SAE-NR-Mod | 2 | 0 |
| Ear Pruritus-non-SAE-R-Mild | 0 | 1 |
| Eccymosis-non-SAE-NR-Mild | 3 | 0 |
| Eccymosis-non-SAE-NR-Mod | 0 | 1 |
| Eczema-non-SAE-NR-Mild | 0 | 2 |
| Eczema-non-SAE-NR-Mod | 5 | 0 |
| Empty Sella Syndrome-non-SAE-NR-Mild | 1 | 0 |
| Epilepsy-non-SAE-NR-Mod | 1 | 0 |
| Epitaxis-non-SAE-NR-Mild | 11 | 5 |
| Erythema-non-SAE-NR-Mild | 1 | 0 |
| Eschar-non-SAE-NR-Mild | 1 | 0 |
| Excoriation-non-SAE-NR-Mild | 8 | 1 |
| Excoriation-non-SAE-NR-Mod | 1 | 0 |
| Eye Haemorrhage-non-SAE-NR-Mild | 1 | 0 |
| Eye Infection-non-SAE-NR-Mild | 1 | 1 |
| Eye Pain-non-SAE-NR-Mild | 0 | 1 |
| Eye Swelling-non-SAE-NR-Mild | 1 | 0 |
| Eyelid Ptosis-non-SAE-NR-Mild | 1 | 0 |
| Facial Bones Fracture-non-SAE-NR-Mod | 0 | 1 |
| Facial Pain-non-SAE-NR-Mod | 1 | 0 |
| Fall-non-SAE-NR-Mild | 3 | 1 |
| Fall-non-SAE-NR-Sev | 0 | 1 |
| Fatigue-non-SAE-NR-Mild | 7 | 1 |
| Fatigue-non-SAE-NR-Mod | 3 | 1 |
| Fatigue-non-SAE-NR-Severe | 1 | 0 |
| Fatigue-non-SAE-R-Mild | 13 | 14 |
| Fatigue-non-SAE-R-Mod | 3 | 7 |
| Femur Fracture-SAE-NR-Sev | 0 | 1 |
| Fibromyalgia-non-SAE-NR-Mod | 2 | 1 |
| Flatulence-non-SAE-NR-Mod | 1 | 0 |
| Flushing-non-SAE-NR-Mod | 1 | 0 |
| Folliculitis-non-SAE-NR-Mild | 1 | 0 |
| Food Poisoning-non-SAE-NR-Mild | 2 | 0 |
| Food Poisoning-non-SAE-NR-Mod | 1 | 0 |
| Foot Fracture-non-SAE-NR-Mod | 1 | 0 |
| Free Haemoglobin Present-non-SAE-NR-Mild | 1 | 0 |
| Free Haemoglobin Present-non-SAE-NR-Mod | 1 | 0 |
| Free Haemoglobin Present-non-SAE-R-Mild | 1 | 0 |
| Free Haemoglobin Present-non-SAE-R-Mod | 1 | 0 |
| Frequent Bowel Movements-non-SAE-NR-Mod | 1 | 0 |
| Fungal Infection-non-SAE-NR-Mild | 1 | 1 |
| Fungal Skin Infection-non-SAE-NR-Mild | 1 | 0 |
Categories presented as Preferred Term-Seriousness-Relatedness-Severity. The following codes are to be used: Seriousness: non-SAE-non-serious AE; SAE-serious AE Relatedness to study drug: R (related to either study drug); NR (not related to either or both study drugs). Study drugs are Immune Globulin Subcutaneous Solution, 10% (IGSC, 10%) and recombinant human hyaluronidase (rHuPH20) Severity: Mild; Mod (Moderate); Severe
| Number of AEs | IGSC, 10% - rHuPH20 | Safety Follow-up - IGSC, 10% or IGIV, 10% Only |
|---|---|---|
| Gastric Stenosis-non-SAE-NR-Mod | 1 | 0 |
| Gastritis-non-SAE-NR-Mild | 1 | 0 |
| Gastroenteritis-non-SAE-NR-Mild | 3 | 0 |
| Gastroenteritis-non-SAE-NR-Mod | 2 | 0 |
| Gastroenteritis Salmonella-non-SAE-NR-Mod | 1 | 0 |
| Gastroenteritis Viral-non-SAE-NR-Mild | 4 | 1 |
| Gastroenteritis Viral-non-SAE-NR-Mod | 3 | 1 |
| Gastrointestinal Viral Infection-non-SAE-NR-Mild | 1 | 0 |
| Gastrooesophageal Reflux Disease-non-SAE-NR-Mild | 3 | 0 |
| Gastrooesophageal Reflux Disease-non-SAE-NR-Mod | 1 | 0 |
| Genital Herpes-non-SAE-NR-Mild | 2 | 2 |
| Genital Herpes-non-SAE-NR-Mod | 0 | 1 |
| Gingival Erosion-non-SAE-NR-Mild | 1 | 0 |
| Gingivitis-non-SAE-NR-Mild | 1 | 0 |
| Glaucoma-non-SAE-NR-Mod | 1 | 0 |
| Glycosuria-non-SAE-NR-Mild | 1 | 0 |
| Gout-non-SAE-NR-Mod | 1 | 0 |
| Haematochezia-non-SAE-NR-Mild | 1 | 0 |
| Haematospermia-non-SAE-NR-Mild | 1 | 0 |
| Haematuria-non-SAE-NR-Mild | 1 | 1 |
| Haemoglobin Decreased-non-SAE-R-Mild | 0 | 1 |
| Haemolysis-non-SAE-R-Mild | 1 | 0 |
| Haemorrhoids-non-SAE-NR-Mild | 2 | 0 |
| Haemorrhoids-non-SAE-NR-Mod | 2 | 0 |
| Hand Fracture-non-SAE-NR-Mod | 1 | 0 |
| Headache-non-SAE-NR-Mild | 22 | 5 |
| Headache-non-SAE-NR-Mod | 4 | 0 |
| Headache-non-SAE-R-Mild | 19 | 34 |
| Headache-non-SAE-R-Mod | 2 | 2 |
| Heart Rate Irregular-non-SAE-NR-Mild | 2 | 1 |
| Herpes Zoster-non-SAE-NR-Mod | 3 | 0 |
| Hiatus Hernia-non-SAE-NR-Mild | 1 | 0 |
| Hydrocele-non-SAE-NR-Mild | 1 | 0 |
| Hypercapnia-non-SAE-Mild | 1 | 0 |
| Hypercholesterolaemia-non-SAE-NR-Mild | 1 | 0 |
| Hypersensitivity-non-SAE-NR-Mild | 2 | 0 |
| Hypertension-non-SAE-NR-Mild | 1 | 1 |
| Hypertension-non-SAE-NR-Mod | 6 | 0 |
| Hypertension-SAE-NR-Mod | 1 | 0 |
| Hypoaesthesia-non-SAE-NR-Mild | 1 | 0 |
| Hypokalaemia-non-SAE-NR-Mild | 0 | 2 |
| Hypothyroidism-non-SAE-NR-Mild | 0 | 2 |
| Hypothyroidism-non-SAE-NR-Mod | 1 | 0 |
| Impetigo-non-SAE-NR-Mild | 2 | 0 |
| Incision Site Pain-non-SAE-NR-Mod | 1 | 0 |
| Increased Upper Airway Secretion-non-SAE-NR-Mild | 1 | 0 |
| Inflammation Of Wound-non-SAE-NR-Mild | 0 | 1 |
| Influenza-non-SAE-NR-Mod | 6 | 4 |
| Influenza Like Illness-non-SAE-NR-Mild | 3 | 0 |
| Influenza Like Illness-non-SAE-NR-Mod | 1 | 0 |
| Infusion Site Abscess-non-SAE-R-Mild | 1 | 0 |
| Infusion Site Bruising-non-SAE-R-Mild | 1 | 0 |
| Infusion Site Discolouration-non-SAE-R-Mild | 1 | 0 |
| Infusion Site Discomfort-non-SAE-R-Mild | 8 | 2 |
| Infusion Site Erythema-non-SAE-R-Mild | 22 | 0 |
| Infusion Site Erythema-non-SAE-R-Mod | 1 | 0 |
| Infusion Site Induration-non-SAE-R-Mild | 2 | 0 |
| Infusion Site Mass-non-SAE-R-Mild | 1 | 0 |
| Infusion Site Oedema-non-SAE-R-Mild | 1 | 0 |
| Infusion Site Pain-non-SAE-NR-Mod | 0 | 2 |
| Infusion Site Pain-non-SAE-R-Mild | 78 | 17 |
| Infusion Site Pain-non-SAE-R-Mod | 6 | 0 |
| Infusion Site Pruritus-non-SAE-R-Mild | 31 | 0 |
| Infusion Site Swelling-non-SAE-R-Mild | 3 | 0 |
| Infusion Site Swelling-non-SAE-R-Sev | 1 | 0 |
| Injection Site Pain-non-SAE-NR-Mild | 1 | 0 |
| Injection Site Pain-non-SAE-R-Mild | 2 | 0 |
| Insomnia-non-SAE-NR-Mild | 5 | 0 |
| Insomnia-non-SAE-NR-Mod | 0 | 1 |
| Intervertebral Disc Degeneration-non-SAE-NR-Mild | 1 | 0 |
| Iron Deficiency Anaemia-non-SAE-NR-Mild | 1 | 0 |
| Irritable Bowel Syndrome-non-SAE-NR-Mod | 2 | 0 |
| Jejunal Stenosis-non-SAE-NR-Mod | 1 | 0 |
| Joint Dislocation-non-SAE-NR-Sev | 1 | 0 |
| Joint Injury-non-SAE-NR-Mild | 2 | 0 |
| Joint Swelling-non-SAE-NR-Mod | 0 | 1 |
| Laceration-non-SAE-NR-Mild | 0 | 1 |
| Ligament Sprain-non-SAE-NR-Mild | 2 | 0 |
| Ligament Sprain-non-SAE-NR-Mod | 1 | 2 |
| Limb Discomfort-non-SAE-NR-Mild | 0 | 1 |
| Liver Function Test Abnormal-non-SAE-NR-Mild | 1 | 0 |
| Local Swelling-non-SAE-NR-Mild | 1 | 0 |
| Local Swelling-non-SAE-R-Mild | 2 | 0 |
| Localised Infection-non-SAE-NR-Mod | 1 | 0 |
| Loss Of Consciousness-non-SAE-NR-Mild | 0 | 1 |
| Lyme Disease-non-SAE-NR-Mild | 2 | 0 |
| Lymph Gland Infection-non-SAE-NR-Mod | 1 | 0 |
| Lymphadenitis-non-SAE-NR-Mod | 0 | 1 |
| Lymphadenitis Bacterial-non-SAE-NR-Mild | 2 | 0 |
| Lymphadenopathy-non-SAE-NR-Mild | 5 | 2 |
| Lymphopenia-non-SAE-NR-Mild | 1 | 0 |
| Malaise-non-SAE-NR-Mild | 2 | 1 |
| Malaise-non-SAE-R-Mild | 1 | 0 |
| Medical Device Pain-non-SAE-NR-Mild | 2 | 0 |
| Memory Impairment-non-SAE-NR-Mild | 1 | 0 |
| Meniscus Injury-non-SAE-NR-Mild | 1 | 0 |
| Menstrual Disorder-non-SAE-NR-Mod | 1 | 0 |
| Mental Status Changes-SAE-NR-Sev | 1 | 0 |
| Micturition Urgency-non-SAE-NR-Mild | 0 | 1 |
| Middle Ear Effusion-non-SAE-NR-Mild | 0 | 1 |
| Migraine-non-SAE-NR-Mild | 3 | 0 |
| Migraine-non-SAE-NR-Mod | 2 | 4 |
| Migraine-non-SAE-NR-Sev | 0 | 1 |
| Migraine-non-SAE-R-Mild | 1 | 2 |
| Migraine-non-SAE-R-Mod | 3 | 1 |
| Mitral Valve Incompetence-non-SAE-NR-Mild | 2 | 0 |
| Molluscum Contagiosum-non-SAE-NR-Mild | 1 | 1 |
| Mouth Ulceration-non-SAE-NR-Mild | 0 | 1 |
| Mucosal Inflammation-non-SAE-NR-Mild | 1 | 0 |
| Muscle Contractions Involuntary-non-SAE-R-Mild | 1 | 0 |
| Muscle Spasms-non-SAE-NR-Mild | 4 | 0 |
| Muscle Strain-non-SAE-NR-Mild | 2 | 0 |
| Muscular Weakness-non-SAE-NR-Mild | 0 | 1 |
| Muscular Weakness-non-SAE-NR-Mod | 1 | 0 |
| Musculoskeletal Pain-non-SAE-NR-Mild | 4 | 0 |
| Musculoskeletal Pain-non-SAE-NR-Mod | 1 | 1 |
| Myalgia-non-SAE-NR-Mild | 2 | 3 |
| Myalgia-non-SAE-NR-Mod | 0 | 1 |
| Myalgia-non-SAE-R-Mild | 23 | 3 |
| Myalgia-non-SAE-R-Mod | 3 | 1 |
Categories presented as Preferred Term-Seriousness, Relatedness, Severity. The following codes are to be used: Seriousness: non-SAE-non-serious AE; SAE-serious AE Relatedness to study drug: R (related to either study drug); NR (not related to either or both study drugs). Study drugs are Immune Globulin Subcutaneous Solution, 10% (IGSC, 10%) and recombinant human hyaluronidase (rHuPH20) Severity: Mild; Mod (Moderate); Severe Preferred terms abbreviated: Infection - Inf.
| Number of AEs | IGSC, 10% - rHuPH20 | Safety Follow-up - IGSC, 10% or IGIV, 10% Only |
|---|---|---|
| Nasal Congestion-non-SAE-NR-Mild | 11 | 5 |
| Nasal Congestion-non-SAE-NR-Mod | 2 | 0 |
| Nasal Discomfort-non-SAE-NR-Mild | 1 | 0 |
| Nasopharyngitis-non-SAE-NR-Mild | 7 | 5 |
| Nasopharyngitis-non-SAE-NR-Mod | 1 | 0 |
| Nausea-non-SAE-NR-Mild | 14 | 5 |
| Nausea-non-SAE-NR-Mod | 4 | 1 |
| Nausea-non-SAE-R-Mild | 25 | 12 |
| Nausea-non-SAE-R-Mod | 3 | 7 |
| Nephrolithiasis-non-SAE-NR-Mild | 0 | 1 |
| Nerve Compression-non-SAE-NR-Mild | 0 | 1 |
| Neutrophil Count Decreased-non-SAE-NR-Mild | 0 | 1 |
| Ocular Hyperaemia-non-SAE-NR-Mild | 0 | 1 |
| Oedema Peripheral-non-SAE-NR-Mild | 4 | 4 |
| Oedema Peripheral-non-SAE-NR-Mod | 4 | 1 |
| Oedema Peripheral-non-SAE-R-Mild | 0 | 1 |
| Oral Candidiasis-non-SAE-NR-Mild | 2 | 0 |
| Oral Herpes-non-SAE-NR-Mild | 7 | 2 |
| Oral Pain-non-SAE-NR-Mild | 0 | 1 |
| Oral Pain-non-SAE-NR-Mod | 0 | 1 |
| Orchitis-non-SAE-NR-Mod | 1 | 0 |
| Oropharyngeal Pain-non-SAE-NR-Mild | 4 | 1 |
| Osteoarthritis-non-SAE-NR-Mild | 2 | 1 |
| Osteoarthritis-non-SAE-NR-Mod | 1 | 0 |
| Osteopenia-non-SAE-NR-Mild | 1 | 0 |
| Osteoporosis-non-SAE-NR-Mild | 0 | 1 |
| Otitis Externa-non-SAE-NR-Mild | 1 | 1 |
| Otitis Externa-non-SAE-NR-Mod | 0 | 1 |
| Otitis Media-non-SAE-NR-Mod | 1 | 1 |
| Pain-non-SAE-NR-Mild | 2 | 0 |
| Pain-non-SAE-R-Mild | 7 | 0 |
| Pain In Extremity-non-SAE-NR-Mild | 4 | 1 |
| Pain In Extremity-non-SAE-R-Sev | 0 | 1 |
| Palpitations-non-SAE-NR-Mild | 2 | 0 |
| Panic Attack-non-SAE-NR-Mild | 0 | 1 |
| Papule-non-SAE-NR-Mild | 1 | 0 |
| Paraesthesia-non-SAE-R-Mild | 1 | 0 |
| Paranasal Cyst-non-SAE-NR-Mild | 1 | 0 |
| Pelvic Pain-non-SAE-NR-Mod | 1 | 0 |
| Pericardial Effusion-non-SAE-NR-Mild | 1 | 0 |
| Perineurial Cyst-non-SAE-NR-Mod | 1 | 0 |
| Periodontal Disease-non-SAE-NR-Mild | 1 | 0 |
| Pharyngitis-non-SAE-NR-Mild | 6 | 1 |
| Pharyngitis-non-SAE-NR-Mod | 0 | 1 |
| Pharyngitis Streptococcal-non-SAE-NR-Mild | 1 | 0 |
| Pleural Effusion-non-SAE-NR-Mild | 1 | 0 |
| Pleural Effusion-non-SAE-NR-Mod | 1 | 0 |
| Pneumonia-non-SAE-NR-Mild | 1 | 0 |
| Pneumonia Bacterial-non-SAE-NR-Mod | 1 | 0 |
| Pneumonia Pseudomonas Aeruginosa-SAE-NR-Sev | 1 | 0 |
| Pollakiuria-non-SAE-NR-Mild | 0 | 1 |
| Pollakiuria-non-SAE-NR-Mod | 1 | 0 |
| Polycystic Ovaries-non-SAE-NR-Mild | 0 | 1 |
| Post Procedural Complication-non-SAE-NR-Mod | 1 | 0 |
| Post Procedural Haemorrhage-non-SAE-NR-Mild | 1 | 0 |
| Post Procedural Swelling-non-SAE-NR-Mild | 1 | 0 |
| Procedural Nausea-non-SAE-NR-Mod | 1 | 0 |
| Procedural Pain-non-SAE-NR-Mild | 0 | 1 |
| Procedural Pain-non-SAE-NR-Mod | 9 | 1 |
| Proctalgia-non-SAE-NR-Mod | 1 | 0 |
| Productive Cough-non-SAE-NR-Mild | 2 | 0 |
| Protein Urine Present-non-SAE-NR-Mild | 1 | 0 |
| Pruritus-non-SAE-NR-Mild | 3 | 3 |
| Pruritus-non-SAE-NR-Mod | 1 | 0 |
| Pruritus-non-SAE-R-Mild | 0 | 3 |
| Pruritus Allergic-non-SAE-NR-Mod | 0 | 1 |
| Pruritus Generalised-non-SAE-R-Mild | 0 | 1 |
| Pulmonary Hypertension-non-SAE-NR-Mild | 1 | 0 |
| Pulmonary Hypertension-non-SAE-NR-Mod | 1 | 0 |
| Pulmonary Vascular Disorder-non-SAE-NR-Mod | 1 | 0 |
| Puncture Site Pain-non-SAE-NR-Mild | 0 | 1 |
| Puncture Site Pain-non-SAE-NR-Mod | 0 | 2 |
| Purpura Senile-non-SAE-NR-Mild | 0 | 1 |
| Pyogenic Granuloma-non-SAE-NR-Mod | 1 | 1 |
| Pyrexia-non-SAE-NR-Mild | 11 | 5 |
| Pyrexia-non-SAE-NR-Mod | 2 | 0 |
| Pyrexia-non-SAE-R-Mild | 3 | 0 |
| Pyuria-non-SAE-NR-Mild | 0 | 1 |
| Rales-non-SAE-NR-Mod | 1 | 1 |
| Rash-non-SAE-NR-Mild | 2 | 1 |
| Rash Generalised-non-SAE-R-Mild | 0 | 1 |
| Rectal Polyp-non-SAE-NR-Mod | 1 | 0 |
| Red Blood Cells Urine Positive-non-SAE-NR-Mild | 1 | 0 |
| Respiratory Tract Congestion-non-SAE-NR-Mild | 2 | 0 |
| Respiratory Tract Congestion-non-SAE-NR-Mod | 1 | 0 |
| Respiratory Tract Infection-non-SAE-NR-Mild | 1 | 0 |
| Respiratory Tract Infection-non-SAE-NR-Mod | 1 | 0 |
| Restless Legs Syndrome-non-SAE-NR-Mild | 1 | 0 |
| Rhinitis-non-SAE-NR-Mild | 2 | 0 |
| Rhinitis Perennial-non-SAE-NR-Mild | 1 | 0 |
| Rhinorrhoea-non-SAE-NR-Mild | 2 | 1 |
| Rhinorrhoea-non-SAE-R-Mild | 0 | 1 |
| Right Atrial Dilatation-non-SAE-NR-Mild | 1 | 0 |
| Rotator Cuff Syndrome-non-SAE-NR-Mild | 1 | 0 |
| Scab-non-SAE-NR-Mild | 1 | 0 |
| Scar-non-SAE-NR-Mild | 1 | 0 |
| Scoliosis-non-SAE-NR-Mild | 0 | 1 |
| Scratch-non-SAE-NR-Mild | 1 | 0 |
| Scrotal Swelling-non-SAE-R-Mild | 3 | 0 |
| Seborrhoeic Keratosis-non-SAE-NR-Mod | 2 | 0 |
| Sinus Congestion-non-SAE-NR-Mild | 1 | 1 |
| Sinus Headache-non-SAE-NR-Mild | 2 | 0 |
| Sinusitis-non-SAE-NR-Mild | 34 | 3 |
| Sinusitis-non-SAE-NR-Mod | 29 | 13 |
| Skin Hyperpigmentation-non-SAE-NR-Mild | 1 | 0 |
| Skin Lesion-non-SAE-NR-Mild | 1 | 0 |
| Skin Mass-non-SAE-NR-Mild | 1 | 1 |
| Sleep Apnoea Syndrome-non-SAE-NR-Mild | 1 | 0 |
| Slow Speech-non-SAE-NR-Mod | 1 | 0 |
| Solar Lentigo-non-SAE-NR-Mild | 1 | 0 |
| Somnolence-non-SAE-NR-Mild | 1 | 0 |
| Speech Disorder-non-SAE-NR-Mild | 0 | 1 |
| Spermatocele-non-SAE-NR-Mild | 1 | 0 |
| Spinal Compression Fracture-non-SAE-NR-Mod | 1 | 0 |
| Spinal Meningeal Cyst-SAE-NR-Sev | 1 | 0 |
| Spinal Osteoarthritis-non-SAE-NR-Mild | 3 | 0 |
| Squamous Cell Carcinoma-non-SAE-NR-Mod | 4 | 2 |
| Stress-non-SAE-NR-Mod | 1 | 0 |
| Suicide Attempt-non-SAE-NR-Sev | 1 | 0 |
| Sunburn-non-SAE-NR-Mild | 1 | 0 |
| Swelling Face-non-SAE-NR-Mod | 1 | 0 |
| Swelling Face-non-SAE-NR-Sev | 0 | 1 |
| Swollen Tongue-non-SAE-NR-Mild | 1 | 0 |
| Synovial Cyst-non-SAE-NR-Mild | 1 | 0 |
| Tachycardia-non-SAE-NR-Mild | 5 | 1 |
| Tachycardia-non-SAE-Mod | 1 | 0 |
| Tendon Disorder-non-SAE-NR-Sev | 1 | 0 |
| Tendonitis-non-SAE-NR-Mild | 2 | 0 |
| Tendonitis-non-SAE-NR-Mod | 1 | 0 |
| Testicular Microlithiasis-non-SAE-NR-Mild | 1 | 0 |
| Testicular Pain-non-SAE-NR-Mod | 1 | 0 |
| Thermal Burn-non-SAE-NR-Mild | 0 | 1 |
| Thinking Abnormal-non-SAE-NR-Mod | 1 | 0 |
| Thrombocytopenia-non-SAE-NR-Mild | 1 | 0 |
| Tibia Fracture-non-SAE-NR-Sev | 1 | 0 |
| Tinea Cruris-non-SAE-NR-Mild | 1 | 0 |
| Tinea Infection-non-SAE-NR-Mild | 1 | 0 |
| Tooth Abscess-non-SAE-NR-Mild | 0 | 1 |
| Tooth Abscess-non-SAE-NR-Mod | 0 | 1 |
| Tooth Fracture-non-SAE-NR-Mod | 1 | 0 |
| Tooth Infection-non-SAE-NR-Mild | 1 | 0 |
| Tooth Infection-non-SAE-NR-Mod | 1 | 0 |
| Toothache-non-SAE-NR-Mod | 0 | 1 |
| Toxicity To Various Agents-SAE-NR-Sev | 1 | 0 |
| Tracheal Stenosis-non-SAE-NR-Mild | 0 | 1 |
| Transient Ischaemic Attack-SAE-NR-Mod | 0 | 1 |
| Traumatic Haematoma-non-SAE-NR-Mild | 1 | 0 |
| Tricuspid Valve Incompetence-non-SAE-NR-Mild | 1 | 0 |
| Trigeminal Neuralgia-non-SAE-NR-Mild | 1 | 0 |
| Tympanic Membrane Scarring-non-SAE-NR-Mild | 1 | 0 |
| Type 2 Diabetes Mellitus-non-SAE-NR-Mod | 2 | 0 |
| Upper Limb Fracture-non-SAE-NR-Mod | 1 | 0 |
| Upper Limb Fracture-non-SAE-NR-Sev | 1 | 0 |
| Upper Respiratory Tract Infection-non-SAE-NR-Mild | 16 | 8 |
| Upper Respiratory Tract Infection-non-SAE-NR-Mod | 13 | 2 |
| Upper-Airway Cough Syndrome-non-SAE-NR-Mild | 1 | 1 |
| Urethritis-non-SAE-NR-Mild | 1 | 0 |
| Urinary Tract Infection-non-SAE-NR-Mild | 4 | 4 |
| Urinary Tract Infection-non-SAE-NR-Mod | 6 | 2 |
| Urticaria-non-SAE-NR-Mild | 0 | 1 |
| Urticaria-non-SAE-R-Mild | 0 | 1 |
| Uterine Polyp-non-SAE-NR-Mod | 1 | 0 |
| Vaginal Prolapse-SAE-NR-Mod | 1 | 0 |
| Vaginitis Bacterial-non-SAE-NR-Mild | 2 | 0 |
| Varicose Vein-non-SAE-NR-Mild | 1 | 0 |
| Vasomotor Rhinitis-non-SAE-NR-Mild | 1 | 0 |
| Vein Pain-non-SAE-NR-Mild | 0 | 1 |
| Ventricular Hypokinesia-non-SAE-NR-Mild | 1 | 0 |
| Vessel Puncture Site Bruise-non-SAE-NR-Mild | 1 | 0 |
| Viral Infection-non-SAE-NR-Mild | 3 | 0 |
| Viral Infection-non-SAE-NR-Mod | 0 | 1 |
| Viral Pharyngitis-non-SAE-NR-Mild | 1 | 0 |
| Viral Pharyngitis-non-SAE-NR-Mod | 0 | 1 |
| Viral Rash-non-SAE-NR-Mod | 1 | 0 |
| Viral Upper Respiratory Tract Inf.-non-SAE-NR-Mild | 29 | 5 |
| Viral Upper Respiratory Tract Inf.-non-SAE-NR-Mod | 1 | 1 |
| Vision Blurred-non-SAE-NR-Mild | 1 | 0 |
| Vitamin B12 Deficiency-non-SAE-NR-Mild | 1 | 0 |
| Vitamin D Decreased-non-SAE-NR-Mild | 0 | 1 |
| Vitamin D Deficiency-non-SAE-NR-Mild | 2 | 0 |
| Vitamin D Deficiency-non-SAE-NR-Mod | 1 | 0 |
| Vomiting-non-SAE-NR-Mild | 13 | 2 |
| Vomiting-non-SAE-NR-Mod | 4 | 1 |
| Vomiting-non-SAE-R-Mod | 0 | 1 |
| Vulvar Dysplasia-non-SAE-NR-Mild | 2 | 0 |
| Vulvovaginal Candidiasis-non-SAE-NR-Mild | 1 | 0 |
| Vulvovaginal Mycotic Infection-non-SAE-NR-Mild | 4 | 1 |
| Vulvovaginal Mycotic Infection-non-SAE-NR-Mod | 2 | 0 |
| Wheezing-non-SAE-NR-Mod | 1 | 0 |
| Wisdom Teeth Removal-non-SAE-NR-Mild | 1 | 0 |
| Wisdom Teeth Removal-non-SAE-NR-Sev | 1 | 0 |
| Wound-non-SAE-NR-Mild | 0 | 1 |
| Wrist Fracture-non-SAE-NR-Mod | 0 | 1 |
| Xeroderma-non-SAE-NR-Mild | 1 | 0 |
Categories presented as Preferred Term-Seriousness-Severity. The following codes are to be used: Seriousness: non-SAE-non-serious AE; SAE-serious AE Severity: Mild; Mod (Moderate); Sev (Severe) Preferred terms abbreviated: ADHD - Attention Deficit/Hyperactivity Disorder COPD - Chronic Obstructive Pulmonary Disease Other abbreviations: Inc. - Increased Dis. - Disease
| Number of AEs per participant | IGSC, 10% - rHuPH20 | Safety Follow-up - IGSC, 10% or IGIV, 10% Only |
|---|---|---|
| Abdominal Distension-non-SAE-Mild | 0.095 | 0 |
| Abdominal Hernia-non-SAE-Mild | 0.016 | 0 |
| Abdominal Mass-non-SAE-Mild | 0 | 0.020 |
| Abdominal Pain-non-SAE-Mild | 0.032 | 0.078 |
| Abdominal Pain-non-SAE-Mod | 0.063 | 0 |
| Abdominal Pain-non-SAE-Severe | 0.016 | 0 |
| Abdominal Pain Upper-non-SAE-Mild | 0.127 | 0 |
| Abdominal Tenderness-non-SAE-Mild | 0.048 | 0 |
| Abnormal Loss of Weight-non-SAE-Mild | 0.016 | 0 |
| Acarodermatitis-non-SAE-Mild | 0.032 | 0.020 |
| Acarodermatitis-non-SAE-Mod | 0.032 | 0 |
| Acne-non-SAE-Mild | 0.016 | 0 |
| Acne-non-SAE-Mod | 0.016 | 0 |
| Actinic Keratosis-non-SAE-Mild | 0.016 | 0 |
| Actinic Keratosis-non-SAE-Mod | 0.016 | 0.039 |
| Activities of Daily Living Impaired-non-SAE-Mod | 0.016 | 0 |
| Acute Sinusitis-non-SAE-Mild | 0 | 0.020 |
| Acute Sinusitis-non-SAE-Mod | 0.016 | 0 |
| Acute Stress Disorder-non-SAE-Mild | 0.016 | 0 |
| Adhesiolysis-SAE-Mod | 0.016 | 0 |
| Age-Related Macular Degeneration-non-SAE-Mild | 0.016 | 0 |
| Agitation-non-SAE-Mild | 0.016 | 0 |
| Aldolase Increased-non-SAE-Mild | 0.016 | 0 |
| Anaphylactic Reaction-non-SAE-Sev | 0 | 0.020 |
| Animal Bite-non-SAE-Mild | 0.016 | 0 |
| Animal Scratch-non-SAE-Mild | 0 | 0.020 |
| Anxiety-non-SAE-Mild | 0.032 | 0 |
| Anxiety-non-SAE-Mod | 0.032 | 0 |
| Aortic Calcification-non-SAE-Mild | 0.016 | 0 |
| Aortic Stenosis-non-SAE-Mild | 0.016 | 0 |
| Aortic Stenosis-non-SAE-Mod | 0.016 | 0 |
| Aortic Valve Incompetence-non-SAE-Mod | 0.016 | 0 |
| Aortic Valve Incompetence-SAE-Sev | 0.016 | 0 |
| Aphthous Stomatitis-non-SAE-Mild | 0.079 | 0.039 |
| Aphthous Stomatitis-non-SAE-Mod | 0.032 | 0 |
| Appendicitis-SAE-Mod | 0.016 | 0 |
| Application Site Erythema-non-SAE-Mild | 0.016 | 0 |
| Arteritis-non-SAE-Mod | 0.016 | 0 |
| Arthralgia-non-SAE-Mild | 0.127 | 0.020 |
| Arthralgia-non-SAE-Mod | 0 | 0.118 |
| Arthropod Bite-non-SAE-Mild | 0.016 | 0.020 |
| Asthenia-non-SAE-Mild | 0.111 | 0 |
| Asthenia-non-SAE-Mod | 0.143 | 0.020 |
| Asthma-non-SAE-Mild | 0.190 | 0.059 |
| Asthma-non-SAE-Mod | 0.317 | 0.059 |
| Ataxia-non-SAE-Mild | 0.032 | 0 |
| Atelectasis-non-SAE-Mild | 0.016 | 0 |
| Atrial Fibrillation-non-SAE-Mild | 0.016 | 0 |
| Atrial Fibrillation-SAE-Mod | 0.016 | 0 |
| ADHD-non-SAE-Mod | 0.016 | 0 |
| Back Pain-non-SAE-Mild | 0.048 | 0.039 |
| Back Pain-non-SAE-Mod | 0.048 | 0.039 |
| Back Pain-non-SAE-Sev | 0 | 0.020 |
| Basal Cell Carcinoma-non-SAE-Mild | 0.016 | 0 |
| Basal Cell Carcinoma-non-SAE-Mod | 0.063 | 0.020 |
| Blepharochalasis-non-SAE-Mild | 0.016 | 0 |
| Blister-non-SAE-Mild | 0.016 | 0 |
| Blood Bicarbonate Decreased-non-SAE-Mild | 0.016 | 0 |
| Blood Creatine Phosphokinase Inc.-non-SAE-Mild | 0.048 | 0 |
| Blood Creatine Phosphokinase Inc.-non-SAE-Mod | 0.032 | 0 |
| Blood Creatinine Increased-non-SAE-Mild | 0.016 | 0.020 |
| Blood Glucose Increased-non-SAE-Mild | 0.063 | 0.020 |
| Blood Urea Increased-non-SAE-Mild | 0 | 0.020 |
| Blood Urine Present-non-SAE-Mild | 0.032 | 0 |
| Body Tinea-non-SAE-Mild | 0.032 | 0 |
| Bone Pain-non-SAE-Mild | 0.016 | 0 |
| Breast Calcifications-non-SAE-Mild | 0.016 | 0 |
| Breast Dysplasia-non-SAE-Mild | 0 | 0.020 |
| Bronchiolitis-non-SAE-Mild | 0.016 | 0 |
| Bronchitis-non-SAE-Mild | 0.175 | 0.098 |
| Bronchitis-non-SAE-Mod | 0.175 | 0.039 |
| Burns Second Degree-non-SAE-Mild | 0.016 | 0 |
| Bursitis-non-SAE-Mild | 0.032 | 0 |
| Candidiasis-non-SAE-Mild | 0.016 | 0 |
| Cardiac Failure Congestive-SAE-Mild | 0.016 | 0 |
| Cardiac Murmur-non-SAE-Mild | 0.032 | 0 |
| Cardiomegaly-non-SAE-Mild | 0 | 0.020 |
| Cardiomegaly-non-SAE-Mod | 0.032 | 0 |
| Cardiomyopathy-non-SAE-Mild | 0.016 | 0 |
| Cataract-non-SAE-Mild | 0.016 | 0.020 |
| Cataract-non-SAE-Mod | 0.032 | 0 |
| Cellulitis-non-SAE-Mild | 0.032 | 0 |
| Cellulitis-non-SAE-Mod | 0.032 | 0.020 |
| Cellulitis-SAE-Mod | 0 | 0.020 |
| Cellulitis Of Male Ext Genital Organ-non-SAE-Mod | 0.016 | 0 |
| Cerebral Small Vessel Ischaemic Dis.-non-SAE-Mild | 0.016 | 0 |
| Cerumen Impaction-non-SAE-Mild | 0.032 | 0.039 |
| Cervical Spinal Stenosis-non-SAE-Mild | 0 | 0.020 |
| Chapped Lips-non-SAE-Mild | 0.016 | 0 |
| Cheilitis-non-SAE-Mild | 0.016 | 0 |
| Chest Discomfort-non-SAE-Mild | 0.016 | 0 |
| Chest Pain-non-SAE-Mild | 0.032 | 0 |
| Chest Pain-non-SAE-Mod | 0.016 | 0 |
| Chills-non-SAE-Mild | 0.206 | 0.020 |
| Chills-non-SAE-Mod | 0.016 | 0 |
| Cholelithiasis-non-SAE-Mild | 0.032 | 0 |
| Chondromalacia-non-SAE-Mod | 0.016 | 0 |
| Chromaturia-non-SAE-Mild | 0.016 | 0 |
| COPD-non-SAE-Mild | 0.032 | 0 |
| COPD-non-SAE-Mod | 0.048 | 0 |
| COPD-SAE-Mod | 0.016 | 0 |
| COPD-SAE-Sev | 0.016 | 0 |
| Chronic Sinusitis-non-SAE-Mild | 0.079 | 0.039 |
| Chronic Sinusitis-non-SAE-Mod | 0.048 | 0.020 |
| Conjunctival Haemorrhage-non-SAE-Mild | 0.016 | 0 |
| Conjunctival Hyperaemia-non-SAE-Mild | 0.032 | 0 |
| Conjunctivitis-non-SAE-Mild | 0 | 0.039 |
| Conjunctivitis Allergic-non-SAE-Mild | 0.016 | 0.020 |
| Conjunctivitis Allergic-non-SAE-Mod | 0 | 0.039 |
| Conjunctivitis Infective-non-SAE-Mild | 0.048 | 0.020 |
| Constipation-non-SAE-Mild | 0.048 | 0.059 |
| Constipation-non-SAE-Mod | 0.048 | 0 |
| Contusion-non-SAE-Mild | 0 | 0.059 |
| Convulsion-non-SAE-Mild | 0.016 | 0 |
| Convulsion-non-SAE-Mod | 0.032 | 0.020 |
| Coombs Direct Test Positive-non-SAE-Mild | 0.016 | 0 |
| Coombs Test Positive-non-SAE-Mild | 0.032 | 0 |
| Corneal Abrasion-non-SAE-Mild | 0.016 | 0 |
| Costochondritis-non-SAE-Mild | 0.016 | 0 |
| Costochondritis-non-SAE-Sev | 0.016 | 0 |
| Cough-non-SAE-Mild | 0.175 | 0.059 |
| Cough-non-SAE-Mod | 0.048 | 0.020 |
| Cryptosporidiosis Infection-SAE-Sev | 0.016 | 0 |
| Cyst-non-SAE-Mild | 0.016 | 0 |
| Cyst-non-SAE-Mod | 0.032 | 0 |
| Cystitis-non-SAE-Mild | 0.016 | 0 |
| Cystocele-SAE-Mod | 0.016 | 0 |
| Decreased Appetite-non-SAE-Mild | 0.063 | 0.157 |
| Decreased Appetite-non-SAE-Mod | 0.032 | 0 |
| Dehydration-non-SAE-Mild | 0.016 | 0 |
| Dehydration-non-SAE-Mod | 0.016 | 0 |
| Dental Caries-non-SAE-Mild | 0.032 | 0 |
| Depression-non-SAE-Mild | 0.016 | 0 |
| Depression-non-SAE-Mod | 0.048 | 0.020 |
| Dermal Cyst-non-SAE-Mod | 0.016 | 0 |
| Dermatitis-non-SAE-Mild | 0.016 | 0 |
| Dermatitis Allergic-non-SAE-Mild | 0 | 0.020 |
| Dermatitis Atopic-non-SAE-Mild | 0.016 | 0 |
| Dermatitis Contact-non-SAE-Mild | 0.048 | 0 |
| Dermatitis Contact-non-SAE-Mod | 0.016 | 0 |
| Dermatitis Psoriasiform-non-SAE-Sev | 0.016 | 0 |
| Device Breakage-non-SAE-Mod | 0.016 | 0 |
| Device Failure-non-SAE-Mod | 0.016 | 0 |
| Diarrhoea-non-SAE-Mild | 0.270 | 0.098 |
| Diarrhoea-non-SAE-Mod | 0.032 | 0 |
| Dizziness-non-SAE-Mild | 0.159 | 0.020 |
| Dizziness-non-SAE-Mod | 0.016 | 0 |
| Drug Eruption-non-SAE-Mod | 0 | 0.020 |
| Drug Hypersensitivity-non-SAE-Mild | 0.048 | 0 |
| Dry Eye-non-SAE-Mild | 0.016 | 0 |
| Dry Eye-non-SAE-Mod | 0.016 | 0.020 |
| Dry Mouth-non-SAE-Mild | 0 | 0.020 |
| Dry Skin-non-SAE-Mild | 0 | 0.020 |
| Dysmenorrhoea-non-SAE-Mild | 0.016 | 0 |
| Dyspepsia-non-SAE-Mild | 0 | 0.059 |
| Dysplastic Naevus-non-SAE-Mod | 0.016 | 0 |
| Dyspnoea-non-SAE-Mild | 0.032 | 0.020 |
| Dyspnoea-non-SAE-Mod | 0.032 | 0 |
| Dysuria-non-SAE-Mild | 0.016 | 0.020 |
| Dysuria-non-SAE-Mod | 0.032 | 0 |
| Ear Infection-non-SAE-Mild | 0.016 | 0 |
| Ear Infection-non-SAE-Mod | 0.048 | 0 |
| Ear Pain-non-SAE-Mild | 0.016 | 0 |
| Ear Pain-non-SAE-Mod | 0.032 | 0 |
| Ear Pruritus-non-SAE-Mild | 0 | 0.020 |
| Ecchymosis-non-SAE-Mild | 0.048 | 0 |
| Ecchymosis-non-SAE-Mod | 0 | 0.020 |
| Eczema-non-SAE-Mild | 0 | 0.039 |
| Eczema-non-SAE-Mod | 0.079 | 0 |
| Empty Sella Syndrome-non-SAE-Mild | 0.016 | 0 |
| Epilepsy-non-SAE-Mod | 0.016 | 0 |
| Epistaxis-non-SAE-Mild | 0.175 | 0.098 |
| Erythema-non-SAE-Mild | 0.016 | 0 |
| Eschar-non-SAE-Mild | 0.016 | 0 |
| Excoriation-non-SAE-Mild | 0.127 | 0.020 |
| Excoriation-non-SAE-Mod | 0.016 | 0 |
| Eye Haemorrhage-non-SAE-Mild | 0.016 | 0 |
| Eye Infection-non-SAE-Mild | 0.016 | 0.020 |
| Eye Pain-non-SAE-Mild | 0 | 0.020 |
| Eye Swelling-non-SAE-Mild | 0.016 | 0 |
| Eyelid Ptosis-non-SAE-Mild | 0.016 | 0 |
| Facial Bones Fracture-non-SAE-Mod | 0 | 0.020 |
| Facial Pain-non-SAE-Mod | 0.016 | 0 |
| Fall-non-SAE-Mild | 0.048 | 0.020 |
| Fall-non-SAE-Sev | 0 | 0.020 |
| Fatigue-non-SAE-Mild | 0.317 | 0.294 |
| Fatigue-non-SAE-Mod | 0.095 | 0.157 |
| Fatigue-non-SAE-Sev | 0.016 | 0 |
| Femur Fracture-SAE-Sev | 0 | 0.020 |
| Fibromyalgia-non-SAE-Mod | 0.032 | 0.020 |
| Flatulence-non-SAE-Mod | 0.016 | 0 |
| Flushing-non-SAE-Mod | 0 | 0.020 |
| Folliculitis-non-SAE-Mild | 0.016 | 0 |
| Food Poisoning-non-SAE-Mild | 0.032 | 0 |
| Food Poisoning-non-SAE-Mod | 0.016 | 0 |
| Foot Fracture-non-SAE-Mod | 0.016 | 0 |
| Free Haemoglobin Present-non-SAE-Mild | 0.032 | 0 |
| Free Haemoglobin Present-non-SAE-Mod | 0.032 | 0 |
| Frequent Bowel Movements-non-SAE-Mod | 0.016 | 0 |
| Fungal Infection-non-SAE-Mild | 0.016 | 0.020 |
| Fungal Skin Infection-non-SAE-Mild | 0.016 | 0 |
Categories presented as Preferred term-Seriousness-Severity. The following codes are to be used: Seriousness: non-SAE-non-serious AE; SAE-serious AE Severity: Mild; Mod (Moderate); Sev (Severe)
| Number of AEs per participant | IGSC, 10% - rHuPH20 | Safety Follow-up - IGSC, 10% or IGIV, 10% Only |
|---|---|---|
| Gastric Stenosis-non-SAE-Mod | 0.016 | 0 |
| Gastritis-non-SAE-Mild | 0.016 | 0 |
| Gastroenteritis-non-SAE-Mild | 0.048 | 0 |
| Gastroenteritis-non-SAE-Mod | 0.032 | 0 |
| Gastroenteritis Salmonella-non-SAE-Mod | 0.016 | 0 |
| Gastroenteritis Viral-non-SAE-Mild | 0.063 | 0.020 |
| Gastroenteritis Viral-non-SAE-Mod | 0.048 | 0.020 |
| Gastrointestinal Viral Infection-non-SAE-Mild | 0.016 | 0 |
| Gastrooesophageal Reflux Disease-non-SAE-Mild | 0.048 | 0 |
| Gastrooesophageal Reflux Disease-non-SAE-Mod | 0.016 | 0 |
| Genital Herpes-non-SAE-Mild | 0.032 | 0.039 |
| Genital Herpes-non-SAE-Mod | 0 | 0.020 |
| Gingival Erosion-non-SAE-Mild | 0.016 | 0 |
| Gingivitis-non-SAE-Mild | 0.016 | 0 |
| Glaucoma-non-SAE-Mod | 0.016 | 0 |
| Glycosuria-non-SAE-Mild | 0.016 | 0 |
| Gout-non-SAE-Mod | 0.016 | 0 |
| Haematochezia-non-SAE-Mild | 0.016 | 0 |
| Haematospermia-non-SAE-Mild | 0.016 | 0 |
| Haematuria-non-SAE-Mild | 0.016 | 0.020 |
| Haemoglobin Decreased-non-SAE-Mild | 0 | 0.020 |
| Haemolysis-non-SAE-Mild | 0.016 | 0 |
| Haemorrhoids-non-SAE-Mild | 0.032 | 0 |
| Haemorrhoids-non-SAE-Mod | 0.032 | 0 |
| Hand Fracture-non-SAE-Mod | 0.016 | 0 |
| Headache-non-SAE-Mild | 0.651 | 0.765 |
| Headache-non-SAE-Mod | 0.095 | 0.039 |
| Heart Rate Irregular-non-SAE-Mild | 0.032 | 0.020 |
| Herpes Zoster-non-SAE-Mod | 0.048 | 0 |
| Hiatus Hernia-non-SAE-Mild | 0.016 | 0 |
| Hydrocele-non-SAE-Mild | 0.016 | 0 |
| Hypercapnia-non-SAE-Mild | 0.016 | 0 |
| Hypercholesterolaemia-non-SAE-Mild | 0.016 | 0 |
| Hypersensitivity-non-SAE-Mild | 0.032 | 0 |
| Hypertension-non-SAE-Mild | 0.016 | 0.020 |
| Hypertension-non-SAE-Mod | 0.095 | 0 |
| Hypertension-SAE-Mod | 0.016 | 0 |
| Hypoaesthesia-non-SAE-Mild | 0.016 | 0 |
| Hypokalaemia-non-SAE-Mild | 0 | 0.039 |
| Hypothyroidism-non-SAE-Mild | 0 | 0.039 |
| Hypothyroidism-non-SAE-Mod | 0.016 | 0 |
| Impetigo-non-SAE-Mild | 0.032 | 0 |
| Incision Site Pain-non-SAE-Mod | 0.016 | 0 |
| Increased Upper Airway Secretion-non-SAE-Mild | 0.016 | 0 |
| Inflammation Of Wound-non-SAE-Mild | 0 | 0.020 |
| Influenza-non-SAE-Mod | 0.095 | 0.078 |
| Influenza Like Illness-non-SAE-Mild | 0.048 | 0 |
| Influenza Like Illness-non-SAE-Mod | 0.016 | 0 |
| Infusion Site Abscess-non-SAE-Mild | 0.016 | 0 |
| Infusion Site Bruising-non-SAE-Mild | 0.016 | 0 |
| Infusion Site Discolouration-non-SAE-Mild | 0.016 | 0 |
| Infusion Site Discomfort-non-SAE-Mild | 0.127 | 0.039 |
| Infusion Site Erythema-non-SAE-Mild | 0.349 | 0 |
| Infusion Site Erythema-non-SAE-Mod | 0.016 | 0 |
| Infusion Site Induration-non-SAE-Mild | 0.032 | 0 |
| Infusion Site Mass-non-SAE-Mild | 0.016 | 0 |
| Infusion Site Oedema-non-SAE-Mild | 0.016 | 0 |
| Infusion Site Pain-non-SAE-Mild | 1.238 | 0.333 |
| Infusion Site Pain-non-SAE-Mod | 0.095 | 0.039 |
| Infusion Site Pruritus-non-SAE-Mild | 0.492 | 0 |
| Infusion Site Swelling-non-SAE-Mild | 0.048 | 0 |
| Infusion Site Swelling-non-SAE-Sev | 0.016 | 0 |
| Injection Site Pain-non-SAE-Mild | 0.048 | 0 |
| Insomnia-non-SAE-Mild | 0.079 | 0 |
| Insomnia-non-SAE-Mod | 0 | 0.020 |
| Intervertebral Disc Degeneration-non-SAE-Mild | 0.016 | 0 |
| Iron Deficiency Anaemia-non-SAE-Mild | 0.016 | 0 |
| Irritable Bowel Syndrome-non-SAE-Mod | 0.032 | 0 |
| Jejunal Stenosis-non-SAE-Mod | 0.016 | 0 |
| Joint Dislocation-non-SAE-Sev | 0.016 | 0 |
| Joint Injury-non-SAE-Mild | 0.032 | 0 |
| Joint Swelling-non-SAE-Mod | 0 | 0.020 |
| Laceration-non-SAE-Mild | 0 | 0.020 |
| Ligament Sprain-non-SAE-Mild | 0.032 | 0 |
| Ligament Sprain-non-SAE-Mod | 0.016 | 0.039 |
| Limb Discomfort-non-SAE-Mild | 0 | 0.020 |
| Liver Function Test Abnormal-non-SAE-Mild | 0.016 | 0 |
| Local Swelling-non-SAE-Mild | 0.048 | 0 |
| Localised Infection-non-SAE-Mod | 0.016 | 0 |
| Loss Of Consciousness-non-SAE-Mild | 0 | 0.020 |
| Lyme Disease-non-SAE-Mild | 0.032 | 0 |
| Lymph Gland Infection-non-SAE-Mod | 0.016 | 0 |
| Lymphadenitis-non-SAE-Mod | 0 | 0.020 |
| Lymphadenitis Bacterial-non-SAE-Mild | 0.032 | 0 |
| Lymphadenopathy-non-SAE-Mild | 0.079 | 0.039 |
| Lymphopenia-non-SAE-Mild | 0.016 | 0 |
| Malaise-non-SAE-Mild | 0.048 | 0.020 |
| Medical Device Pain-non-SAE-Mild | 0.032 | 0 |
| Memory Impairment-non-SAE-Mild | 0.016 | 0 |
| Meniscus Injury-non-SAE-Mild | 0.016 | 0 |
| Menstrual Disorder-non-SAE-Mod | 0.016 | 0 |
| Mental Status Changes-SAE-Sev | 0.016 | 0 |
| Micturition Urgency-non-SAE-Mild | 0 | 0.020 |
| Middle Ear Effusion-non-SAE-Mild | 0 | 0.020 |
| Migraine-non-SAE-Mild | 0.063 | 0.039 |
| Migraine-non-SAE-Mod | 0.079 | 0.098 |
| Migraine-non-SAE-Sev | 0 | 0.020 |
| Mitral Valve Incompetence-non-SAE-Mild | 0.032 | 0 |
| Molluscum Contagiosum-non-SAE-Mild | 0.016 | 0.020 |
| Mouth Ulceration-non-SAE-Mild | 0 | 0.020 |
| Mucosal Inflammation-non-SAE-Mild | 0.016 | 0 |
| Muscle Contractions Involuntary-non-SAE-Mild | 0.016 | 0 |
| Muscle Spasms-non-SAE-Mild | 0.063 | 0 |
| Muscle Strain-non-SAE-Mild | 0.032 | 0 |
| Muscular Weakness-non-SAE-Mild | 0 | 0.020 |
| Muscular Weakness-non-SAE-Mod | 0.016 | 0 |
| Musculoskeletal Pain-non-SAE-Mild | 0.063 | 0 |
| Musculoskeletal Pain-non-SAE-Mod | 0.016 | 0.020 |
| Myalgia-non-SAE-Mild | 0.397 | 0.118 |
| Myalgia-non-SAE-Mod | 0.048 | 0.039 |
Categories presented as Preferred term-Seriousness-Severity. The following codes are to be used: Seriousness: non-SAE-non-serious AE; SAE-serious AE Severity: Mild; Mod (Moderate); Sev (Severe)
| Number of AEs per participant | IGSC, 10% - rHuPH20 | Safety Follow-up - IGSC, 10% or IGIV, 10% Only |
|---|---|---|
| Nasal Congestion-non-SAE-Mild | 0.175 | 0.098 |
| Nasal Congestion-non-SAE-Mod | 0.032 | 0 |
| Nasal Discomfort-non-SAE-Mild | 0.016 | 0 |
| Nasopharyngitis-non-SAE-Mild | 0.111 | 0.098 |
| Nasopharyngitis-non-SAE-Mod | 0.016 | 0 |
| Nausea-non-SAE-Mild | 0.619 | 0.333 |
| Nausea-non-SAE-Mod | 0.111 | 0.157 |
| Nephrolithiasis-non-SAE-Mild | 0 | 0.020 |
| Nerve Compression-non-SAE-Mild | 0 | 0.020 |
| Neutrophil Count Decreased-non-SAE-Mild | 0 | 0.020 |
| Ocular Hyperaemia-non-SAE-Mild | 0 | 0.020 |
| Oedema Peripheral-non-SAE-Mild | 0.063 | 0.098 |
| Oedema Peripheral-non-SAE-Mod | 0.063 | 0.020 |
| Oral Candidiasis-non-SAE-Mild | 0.032 | 0 |
| Oral Herpes-non-SAE-Mild | 0.111 | 0.039 |
| Oral Pain-non-SAE-Mild | 0 | 0.020 |
| Oral Pain-non-SAE-Mod | 0 | 0.020 |
| Orchitis-non-SAE-Mod | 0.016 | 0 |
| Oropharyngeal Pain-non-SAE-Mild | 0.063 | 0.020 |
| Osteoarthritis-non-SAE-Mild | 0.032 | 0.020 |
| Osteoarthritis-non-SAE-Mod | 0.016 | 0 |
| Osteopenia-non-SAE-Mild | 0.016 | 0 |
| Osteoporosis-non-SAE-Mild | 0 | 0.020 |
| Otitis Externa-non-SAE-Mild | 0.016 | 0.020 |
| Otitis Externa-non-SAE-Mod | 0 | 0.020 |
| Otitis Media-non-SAE-Mod | 0.016 | 0.020 |
| Pain-non-SAE-Mild | 0.143 | 0 |
| Pain In Extremity-non-SAE-Mild | 0.063 | 0.020 |
| Pain In Extremity-non-SAE-Sev | 0 | 0.020 |
| Palpitations-non-SAE-Mild | 0.032 | 0 |
| Panic Attack-non-SAE-Mild | 0 | 0.020 |
| Papule-non-SAE-Mild | 0.016 | 0 |
| Paraesthesia-non-SAE-Mild | 0.016 | 0 |
| Paranasal Cyst-non-SAE-Mild | 0.016 | 0 |
| Pelvic Pain-non-SAE-Mod | 0.016 | 0 |
| Pericardial Effusion-non-SAE-Mild | 0.016 | 0 |
| Perineurial Cyst-non-SAE-Mod | 0.016 | 0 |
| Periodontal Disease-non-SAE-Mild | 0.016 | 0 |
| Pharyngitis-non-SAE-Mild | 0.095 | 0.020 |
| Pharyngitis-non-SAE-Mod | 0 | 0.020 |
| Pharyngitis Streptococcal-non-SAE-Mild | 0.016 | 0 |
| Pleural Effusion-non-SAE-Mild | 0.016 | 0 |
| Pleural Effusion-non-SAE-Mod | 0.016 | 0 |
| Pneumonia-non-SAE-Mild | 0.016 | 0 |
| Pneumonia Bacterial-non-SAE-Mod | 0.016 | 0 |
| Pneumonia Pseudomonas Aeruginosa-SAE-Sev | 0.016 | 0 |
| Pollakiuria-non-SAE-Mild | 0 | 0.020 |
| Pollakiuria-non-SAE-Mod | 0.016 | 0 |
| Polycystic Ovaries-non-SAE-Mild | 0 | 0.020 |
| Post Procedural Complication-non-SAE-Mod | 0.016 | 0 |
| Post Procedural Haemorrhage-non-SAE-Mild | 0.016 | 0 |
| Post Procedural Swelling-non-SAE-Mild | 0.016 | 0 |
| Procedural Nausea-non-SAE-Mod | 0.016 | 0 |
| Procedural Pain-non-SAE-Mild | 0 | 0.020 |
| Procedural Pain-non-SAE-Mod | 0.143 | 0.020 |
| Proctalgia-non-SAE-Mod | 0.016 | 0 |
| Productive Cough-non-SAE-Mild | 0.032 | 0 |
| Protein Urine Present-non-SAE-Mild | 0.016 | 0 |
| Pruritus-non-SAE-Mild | 0.048 | 0.118 |
| Pruritus-non-SAE-Mod | 0.016 | 0 |
| Pruritus Allergic-non-SAE-Mod | 0 | 0.020 |
| Pruritus Generalised-non-SAE-Mild | 0 | 0.020 |
| Pulmonary Hypertension-non-SAE-Mild | 0.016 | 0 |
| Pulmonary Hypertension-non-SAE-Mod | 0.016 | 0 |
| Pulmonary Vascular Disorder-non-SAE-Mod | 0.016 | 0 |
| Puncture Site Pain-non-SAE-Mild | 0 | 0.020 |
| Puncture Site Pain-non-SAE-Mod | 0 | 0.039 |
| Purpura Senile-non-SAE-Mild | 0 | 0.020 |
| Pyogenic Granuloma-non-SAE-Mod | 0.016 | 0.020 |
| Pyrexia-non-SAE-Mild | 0.222 | 0.098 |
| Pyrexia-non-SAE-Mod | 0.032 | 0 |
| Pyuria-non-SAE-Mild | 0 | 0.020 |
| Rales-non-SAE-Mod | 0.016 | 0.020 |
| Rash-non-SAE-Mild | 0.032 | 0.020 |
| Rash Generalised-non-SAE-Mild | 0 | 0.020 |
| Rectal Polyp-non-SAE-Mod | 0.016 | 0 |
| Red Blood Cells Urine Positive-non-SAE-Mild | 0.016 | 0 |
| Respiratory Tract Congestion-non-SAE-Mild | 0.032 | 0 |
| Respiratory Tract Congestion-non-SAE-Mod | 0.016 | 0 |
| Respiratory Tract Infection-non-SAE-Mild | 0.016 | 0 |
| Respiratory Tract Infection-non-SAE-Mod | 0.016 | 0 |
| Restless Legs Syndrome-non-SAE-Mild | 0.016 | 0 |
| Rhinitis-non-SAE-Mild | 0.032 | 0 |
| Rhinitis Perennial-non-SAE-Mild | 0.016 | 0 |
| Rhinorrhoea-non-SAE-Mild | 0.032 | 0.039 |
| Right Atrial Dilatation-non-SAE-Mild | 0.016 | 0 |
| Rotator Cuff Syndrome-non-SAE-Mild | 0.016 | 0 |
| Scab-non-SAE-Mild | 0.016 | 0 |
| Scar-non-SAE-Mild | 0.016 | 0 |
| Scoliosis-non-SAE-Mild | 0 | 0.020 |
| Scratch-non-SAE-Mild | 0.016 | 0 |
| Scrotal Swelling-non-SAE-Mild | 0.048 | 0 |
| Seborrhoeic Keratosis-non-SAE-Mod | 0.032 | 0 |
| Sinus Congestion-non-SAE-Mild | 0.016 | 0.020 |
| Sinus Headache-non-SAE-Mild | 0.032 | 0 |
| Sinusitis-non-SAE-Mild | 0.540 | 0.059 |
| Sinusitis-non-SAE-Mod | 0.460 | 0.255 |
| Skin Hyperpigmentation-non-SAE-Mild | 0.016 | 0 |
| Skin Lesion-non-SAE-Mild | 0.016 | 0 |
| Skin Mass-non-SAE-Mild | 0.016 | 0.020 |
| Sleep Apnoea Syndrome-non-SAE-Mild | 0.016 | 0 |
| Slow Speech-non-SAE-Mod | 0.016 | 0 |
| Solar Lentigo-non-SAE-Mild | 0.016 | 0 |
| Somnolence-non-SAE-Mild | 0.016 | 0 |
| Speech Disorder-non-SAE-Mild | 0 | 0.020 |
| Spermatocele-non-SAE-Mild | 0.016 | 0 |
| Spinal Compression Fracture-non-SAE-Mod | 0.016 | 0 |
| Spinal Meningeal Cyst-SAE-Sev | 0.016 | 0 |
| Spinal Osteoarthritis-non-SAE-Mild | 0.048 | 0 |
| Squamous Cell Carcinoma-non-SAE-Mod | 0.063 | 0.039 |
| Stress-non-SAE-Mod | 0.016 | 0 |
| Suicide Attempt-non-SAE-Sev | 0.016 | 0 |
| Sunburn-non-SAE-Mild | 0.016 | 0 |
| Swelling Face-non-SAE-Mod | 0.016 | 0 |
| Swelling Face-non-SAE-Sev | 0 | 0.020 |
| Swollen Tongue-non-SAE-Mild | 0.016 | 0 |
| Synovial Cyst-non-SAE-Mild | 0.016 | 0 |
| Tachycardia-non-SAE-Mild | 0.079 | 0.020 |
| Tachycardia-non-SAE-Mod | 0.016 | 0 |
| Tendon Disorder-non-SAE-Sev | 0.016 | 0 |
| Tendonitis-non-SAE-Mild | 0.032 | 0 |
| Tendonitis-non-SAE-Mod | 0.016 | 0 |
| Testicular Microlithiasis-non-SAE-Mild | 0.016 | 0 |
| Testicular Pain-non-SAE-Mod | 0.016 | 0 |
| Thermal Burn-non-SAE-Mild | 0 | 0.020 |
| Thinking Abnormal-non-SAE-Mod | 0.016 | 0 |
| Thrombocytopenia-non-SAE-Mild | 0.016 | 0 |
| Tibia Fracture-non-SAE-Sev | 0.016 | 0 |
| Tinea Cruris-non-SAE-Mild | 0.016 | 0 |
| Tinea Infection-non-SAE-Mild | 0.016 | 0 |
| Tooth Abscess-non-SAE-Mild | 0 | 0.020 |
| Tooth Abscess-non-SAE-Mod | 0 | 0.020 |
| Tooth Fracture-non-SAE-Mod | 0.016 | 0 |
| Tooth Infection-non-SAE-Mild | 0.016 | 0 |
| Tooth Infection-non-SAE-Mod | 0.016 | 0 |
| Toothache-non-SAE-Mod | 0 | 0.020 |
| Toxicity To Various Agents-SAE-Sev | 0.016 | 0 |
| Tracheal Stenosis-non-SAE-Mild | 0 | 0.020 |
| Transient Ischaemic Attack-SAE-Mod | 0 | 0.020 |
| Traumatic Haematoma-non-SAE-Mild | 0.016 | 0 |
| Tricuspid Valve Incompetence-non-SAE-Mild | 0.016 | 0 |
| Trigeminal Neuralgia-non-SAE-Mild | 0.016 | 0 |
| Tympanic Membrane Scarring-non-SAE-Mild | 0.016 | 0 |
| Type 2 Diabetes Mellitus-non-SAE-Mod | 0.032 | 0 |
| Upper Limb Fracture-non-SAE-Mod | 0.016 | 0 |
| Upper Limb Fracture-non-SAE-Sev | 0.016 | 0 |
| Upper Respiratory Tract Infection-non-SAE-Mild | 0.254 | 0.157 |
| Upper Respiratory Tract Infection-non-SAE-Mod | 0.206 | 0.039 |
| Upper-Airway Cough Syndrome-non-SAE-Mild | 0.016 | 0.020 |
| Urethritis-non-SAE-Mild | 0.016 | 0 |
| Urinary Tract Infection-non-SAE-Mild | 0.063 | 0.078 |
| Urinary Tract Infection-non-SAE-Mod | 0.095 | 0.039 |
| Urticaria-non-SAE-Mild | 0 | 0.039 |
| Uterine Polyp-non-SAE-Mod | 0.016 | 0 |
| Vaginal Prolapse-SAE-Mod | 0.016 | 0 |
| Vaginitis Bacterial-non-SAE-Mild | 0.032 | 0 |
| Varicose Vein-non-SAE-Mild | 0.016 | 0 |
| Vasomotor Rhinitis-non-SAE-Mild | 0.016 | 0 |
| Vein Pain-non-SAE-Mild | 0 | 0.020 |
| Ventricular Hypokinesia-non-SAE-Mild | 0.016 | 0 |
| Vessel Puncture Site Bruise-non-SAE-Mild | 0.016 | 0 |
| Viral Infection-non-SAE-Mild | 0.048 | 0 |
| Viral Infection-non-SAE-Mod | 0 | 0.020 |
| Viral Pharyngitis-non-SAE-Mild | 0.016 | 0 |
| Viral Pharyngitis-non-SAE-Mod | 0 | 0.020 |
| Viral Rash-non-SAE-Mod | 0.016 | 0 |
| Viral Upper Respiratory Tract Inf.-non-SAE-Mild | 0.460 | 0.098 |
| Viral Upper Respiratory Tract Inf-non-SAE-Mod | 0.016 | 0.020 |
| Vision Blurred-non-SAE-Mild | 0.016 | 0 |
| Vitamin B12 Deficiency-non-SAE-Mild | 0.016 | 0 |
| Vitamin D Decreased-non-SAE-Mild | 0 | 0.020 |
| Vitamin D Deficiency-non-SAE-Mild | 0.032 | 0 |
| Vitamin D Deficiency-non-SAE-Mod | 0.016 | 0 |
| Vomiting-non-SAE-Mild | 0.206 | 0.039 |
| Vomiting-non-SAE-Mod | 0.063 | 0.039 |
| Vulvar Dysplasia-non-SAE-Mild | 0.032 | 0 |
| Vulvovaginal Candidiasis-non-SAE-Mild | 0.016 | 0 |
| Vulvovaginal Mycotic Infection-non-SAE-Mild | 0.063 | 0.020 |
| Vulvovaginal Mycotic Infection-non-SAE-Mod | 0.032 | 0 |
| Wheezing-non-SAE-Mod | 0.016 | 0 |
| Wisdom Teeth Removal-non-SAE-Mild | 0.016 | 0 |
| Wisdom Teeth Removal-non-SAE-Sev | 0.016 | 0 |
| Wound-non-SAE-Mild | 0 | 0.020 |
| Wrist Fracture-non-SAE-Mod | 0 | 0.020 |
| Xeroderma-non-SAE-Mild | 0.016 | 0 |
Categories presented as Preferred term-Seriousness-Severity. The following codes are to be used: Seriousness: non-SAE-non-serious adverse event; SAE- serious adverse event Severity: Mild; Mod (Moderate); Sev (Severe) Preferred terms abbreviated: ADHD - Attention Deficit/Hyperactivity Disorder COPD - Chronic Obstructive Pulmonary Disease Other abbreviations: Inc. - Increased Dis. - Disease
| Number of AEs per infusion | IGSC, 10% - rHuPH20 | Safety Follow-up - IGSC, 10% or IGIV, 10% Only |
|---|---|---|
| Abdominal Distension-non-SAE-Mild | 0.004 | 0 |
| Abdominal Hernia-non-SAE-Mild | 0.001 | 0 |
| Abdominal Mass-non-SAE-Mild | 0.002 | 0 |
| Abdominal Pain-non-SAE-Mild | 0.001 | 0.007 |
| Abdominal Pain-non-SAE-Mod | 0.003 | 0 |
| Abdominal Pain-non-SAE-Severe | 0.001 | 0 |
| Abdominal Pain Upper-non-SAE-Mild | 0.005 | 0 |
| Abdominal Tenderness-non-SAE-Mild | 0.002 | 0 |
| Abnormal Loss of Weight-non-SAE-Mild | 0.001 | 0 |
| Acarodermatitis-non-SAE-Mild | 0.001 | 0.002 |
| Acarodermatitis-non-SAE-Mod | 0.001 | 0 |
| Acne-non-SAE-Mild | 0.001 | 0 |
| Acne-non-SAE-Mod | 0.001 | 0 |
| Actinic Keratosis-non-SAE-Mild | 0.001 | 0 |
| Actinic Keratosis-non-SAE-Mod | 0.001 | 0.003 |
| Activities of Daily Living Impaired-non-SAE-Mod | 0.001 | 0 |
| Acute Sinusitis-non-SAE-Mild | 0 | 0.002 |
| Acute Sinusitis-non-SAE-Mod | 0.001 | 0 |
| Acute Stress Disorder-non-SAE-Mild | 0.001 | 0 |
| Adhesiolysis-SAE-Mod | 0.001 | 0 |
| Age-Related Macular Degeneration-non-SAE-Mild | 0.001 | 0 |
| Agitation-non-SAE-Mild | 0.001 | 0 |
| Aldolase Increased-non-SAE-Mild | 0.001 | 0 |
| Anaphylactic Reaction-non-SAE-Sev | 0 | 0.002 |
| Animal Bite-non-SAE-Mild | 0.001 | 0 |
| Animal Scratch-non-SAE-Mild | 0 | 0.002 |
| Anxiety-non-SAE-Mild | 0.001 | 0 |
| Anxiety-non-SAE-Mod | 0.001 | 0 |
| Aortic Calcification-non-SAE-Mild | 0.001 | 0 |
| Aortic Stenosis-non-SAE-Mild | 0.001 | 0 |
| Aortic Stenosis-non-SAE-Mod | 0.001 | 0 |
| Aortic Valve Incompetence-non-SAE-Mod | 0.001 | 0 |
| Aortic Valve Incompetence-SAE-Sev | 0.001 | 0 |
| Aphthous Stomatitis-non-SAE-Mild | 0.003 | 0.003 |
| Aphthous Stomatitis-non-SAE-Mod | 0.001 | 0 |
| Appendicitis-SAE-Mod | 0.001 | 0 |
| Application Site Erythema-non-SAE-Mild | 0.001 | 0 |
| Arteritis-non-SAE-Mod | 0.001 | 0 |
| Arthralgia-non-SAE-Mild | 0.005 | 0.002 |
| Arthralgia-non-SAE-Mod | 0 | 0.010 |
| Arthropod Bite-non-SAE-Mild | 0.001 | 0.002 |
| Asthenia-non-SAE-Mild | 0.004 | 0 |
| Asthenia-non-SAE-Mod | 0.006 | 0.002 |
| Asthma-non-SAE-Mild | 0.008 | 0.005 |
| Asthma-non-SAE-Mod | 0.013 | 0.005 |
| Ataxia-non-SAE-Mild | 0.001 | 0 |
| Atelectasis-non-SAE-Mild | 0.001 | 0 |
| Atrial Fibrillation-non-SAE-Mild | 0.001 | 0 |
| Atrial Fibrillation-SAE-Mod | 0.001 | 0 |
| ADHD-non-SAE-Mod | 0.001 | 0 |
| Back Pain-non-SAE-Mild | 0.002 | 0.003 |
| Back Pain-non-SAE-Mod | 0.002 | 0.003 |
| Back Pain-non-SAE-Sev | 0 | 0.002 |
| Basal Cell Carcinoma-non-SAE-Mild | 0.001 | 0 |
| Basal Cell Carcinoma-non-SAE-Mod | 0.003 | 0.002 |
| Blepharochalasis-non-SAE-Mild | 0.001 | 0 |
| Blister-non-SAE-Mild | 0.001 | 0 |
| Blood Bicarbonate Decreased-non-SAE-Mild | 0.001 | 0 |
| Blood Creatine Phosphokinase Inc.-non-SAE-Mild | 0.002 | 0 |
| Blood Creatine Phosphokinase Inc.-non-SAE-Mod | 0.001 | 0 |
| Blood Creatinine Increased-non-SAE-Mild | 0.001 | 0.002 |
| Blood Glucose Increased-non-SAE-Mild | 0.003 | 0.002 |
| Blood Urea Increased-non-SAE-Mild | 0 | 0.002 |
| Blood Urine Present-non-SAE-Mild | 0.001 | 0 |
| Body Tinea-non-SAE-Mild | 0.001 | 0 |
| Bone Pain-non-SAE-Mild | 0.001 | 0 |
| Breast Calcifications-non-SAE-Mild | 0.001 | 0 |
| Breast Dysplasia-non-SAE-Mild | 0 | 0.002 |
| Bronchiolitis-non-SAE-Mild | 0.001 | 0 |
| Bronchitis-non-SAE-Mild | 0.007 | 0.008 |
| Bronchitis-non-SAE-Mod | 0.007 | 0.003 |
| Burns Second Degree-non-SAE-Mild | 0.001 | 0 |
| Bursitis-non-SAE-Mild | 0.001 | 0 |
| Candidiasis-non-SAE-Mild | 0.001 | 0 |
| Cardiac Failure Congestive-SAE-Mild | 0.001 | 0 |
| Cardiac Murmur-non-SAE-Mild | 0.001 | 0 |
| Cardiomegaly-non-SAE-Mild | 0 | 0.002 |
| Cardiomegaly-non-SAE-Mod | 0.001 | 0 |
| Cardiomyopathy-non-SAE-Mild | 0.001 | 0 |
| Cataract-non-SAE-Mild | 0.001 | 0.002 |
| Cataract-non-SAE-Mod | 0.001 | 0 |
| Cellulitis-non-SAE-Mild | 0.001 | 0 |
| Cellulitis-non-SAE-Mod | 0.001 | 0.002 |
| Cellulitis-SAE-Mod | 0 | 0.002 |
| Cellulitis Of Male Ext Genital Organ-non-SAE-Mod | 0.001 | 0 |
| Cerebral Small Vessel Ischaemic Dis.-non-SAE-Mild | 0.001 | 0 |
| Cerumen Impaction-non-SAE-Mild | 0.001 | 0.003 |
| Cervical Spinal Stenosis-non-SAE-Mild | 0 | 0.002 |
| Chapped Lips-non-SAE-Mild | 0.001 | 0 |
| Cheilitis-non-SAE-Mild | 0.001 | 0 |
| Chest Discomfort-non-SAE-Mild | 0.001 | 0 |
| Chest Pain-non-SAE-Mild | 0.001 | 0 |
| Chest Pain-non-SAE-Mod | 0.001 | 0 |
| Chills-non-SAE-Mild | 0.008 | 0.002 |
| Chills-non-SAE-Mod | 0.001 | 0 |
| Cholelithiasis-non-SAE-Mild | 0.001 | 0 |
| Chondromalacia-non-SAE-Mod | 0.001 | 0 |
| Chromaturia-non-SAE-Mild | 0.001 | 0 |
| COPD-non-SAE-Mild | 0.001 | 0 |
| COPD-non-SAE-Mod | 0.002 | 0 |
| COPD-SAE-Mod | 0.001 | 0 |
| COPD-SAE-Sev | 0.001 | 0 |
| Chronic Sinusitis-non-SAE-Mild | 0.003 | 0.003 |
| Chronic Sinusitis-non-SAE-Mod | 0.002 | 0.002 |
| Conjunctival Haemorrhage-non-SAE-Mild | 0.001 | 0 |
| Conjunctival Hyperaemia-non-SAE-Mild | 0.001 | 0 |
| Conjunctivitis-non-SAE-Mild | 0 | 0.003 |
| Conjunctivitis Allergic-non-SAE-Mild | 0.001 | 0.002 |
| Conjunctivitis Allergic-non-SAE-Mod | 0 | 0.003 |
| Conjunctivitis Infective-non-SAE-Mild | 0.002 | 0.002 |
| Constipation-non-SAE-Mild | 0.002 | 0.005 |
| Constipation-non-SAE-Mod | 0.002 | 0 |
| Contusion-non-SAE-Mild | 0 | 0.005 |
| Convulsion-non-SAE-Mild | 0.001 | 0 |
| Convulsion-non-SAE-Mod | 0.001 | 0.002 |
| Coombs Direct Test Positive-non-SAE-Mild | 0.001 | 0 |
| Coombs Test Positive-non-SAE-Mild | 0.001 | 0 |
| Corneal Abrasion-non-SAE-Mild | 0.001 | 0 |
| Costochondritis-non-SAE-Mild | 0.001 | 0 |
| Costochondritis-non-SAE-Sev | 0.001 | 0 |
| Cough-non-SAE-Mild | 0.007 | 0.005 |
| Cough-non-SAE-Mod | 0.002 | 0.002 |
| Cryptosporidiosis Infection-SAE-Sev | 0.001 | 0 |
| Cyst-non-SAE-Mild | 0.001 | 0 |
| Cyst-non-SAE-Mod | 0.001 | 0 |
| Cystitis-non-SAE-Mild | 0.001 | 0 |
| Cystocele-SAE-Mod | 0.001 | 0 |
| Decreased Appetite-non-SAE-Mild | 0.003 | 0.013 |
| Decreased Appetite-non-SAE-Mod | 0.001 | 0 |
| Dehydration-non-SAE-Mild | 0.001 | 0 |
| Dehydration-non-SAE-Mod | 0.001 | 0 |
| Dental Caries-non-SAE-Mild | 0.001 | 0 |
| Depression-non-SAE-Mild | 0.001 | 0 |
| Depression-non-SAE-Mod | 0.002 | 0.002 |
| Dermal Cyst-non-SAE-Mod | 0.001 | 0 |
| Dermatitis-non-SAE-Mild | 0.001 | 0 |
| Dermatitis Allergic-non-SAE-Mild | 0 | 0.002 |
| Dermatitis Atopic-non-SAE-Mild | 0.001 | 0 |
| Dermatitis Contact-non-SAE-Mild | 0.002 | 0 |
| Dermatitis Contact-non-SAE-Mod | 0.001 | 0 |
| Dermatitis Psoriasiform-non-SAE-Sev | 0.001 | 0 |
| Device Breakage-non-SAE-Mod | 0.001 | 0 |
| Device Failure-non-SAE-Mod | 0.001 | 0 |
| Diarrhoea-non-SAE-Mild | 0.011 | 0.008 |
| Diarrhoea-non-SAE-Mod | 0.001 | 0 |
| Dizziness-non-SAE-Mild | 0.006 | 0.002 |
| Dizziness-non-SAE-Mod | 0.001 | 0 |
| Drug Eruption-non-SAE-Mod | 0 | 0.002 |
| Drug Hypersensitivity-non-SAE-Mild | 0.002 | 0 |
| Dry Eye-non-SAE-Mild | 0.001 | 0 |
| Dry Eye-non-SAE-Mod | 0.001 | 0.002 |
| Dry Mouth-non-SAE-Mild | 0 | 0.002 |
| Dry Skin-non-SAE-Mild | 0 | 0.002 |
| Dysmenorrhoea-non-SAE-Mild | 0.001 | 0 |
| Dyspepsia-non-SAE-Mild | 0 | 0.005 |
| Dysplastic Naevus-non-SAE-Mod | 0.001 | 0 |
| Dyspnoea-non-SAE-Mild | 0.001 | 0.002 |
| Dyspnoea-non-SAE-Mod | 0.001 | 0 |
| Dysuria-non-SAE-Mild | 0.001 | 0.002 |
| Dysuria-non-SAE-Mod | 0.001 | 0 |
| Ear Infection-non-SAE-Mild | 0.001 | 0 |
| Ear Infection-non-SAE-Mod | 0.002 | 0 |
| Ear Pain-non-SAE-Mild | 0.001 | 0 |
| Ear Pain-non-SAE-Mod | 0.001 | 0 |
| Ear Pruritus-non-SAE-Mild | 0 | 0.002 |
| Ecchymosis-non-SAE-Mild | 0.002 | 0 |
| Ecchymosis-non-SAE-Mod | 0 | 0.002 |
| Eczema-non-SAE-Mild | 0 | 0.003 |
| Eczema-non-SAE-Mod | 0.003 | 0 |
| Empty Sella Syndrome-non-SAE-Mild | 0.001 | 0 |
| Epilepsy-non-SAE-Mod | 0.001 | 0 |
| Epistaxis-non-SAE-Mild | 0.007 | 0.008 |
| Erythema-non-SAE-Mild | 0.001 | 0 |
| Eschar-non-SAE-Mild | 0.001 | 0 |
| Excoriation-non-SAE-Mild | 0.005 | 0.002 |
| Excoriation-non-SAE-Mod | 0.001 | 0 |
| Eye Haemorrhage-non-SAE-Mild | 0.001 | 0 |
| Eye Infection-non-SAE-Mild | 0.001 | 0.002 |
| Eye Pain-non-SAE-Mild | 0 | 0.002 |
| Eye Swelling-non-SAE-Mild | 0.001 | 0 |
| Eyelid Ptosis-non-SAE-Mild | 0.001 | 0 |
| Facial Bones Fracture-non-SAE-Mod | 0 | 0.002 |
| Facial Pain-non-SAE-Mod | 0.001 | 0 |
| Fall-non-SAE-Mild | 0.002 | 0.002 |
| Fall-non-SAE-Sev | 0 | 0.002 |
| Fatigue-non-SAE-Mild | 0.013 | 0.025 |
| Fatigue-non-SAE-Mod | 0.004 | 0.013 |
| Fatigue-non-SAE-Sev | 0.001 | 0 |
| Femur Fracture-SAE-Sev | 0 | 0.002 |
| Fibromyalgia-non-SAE-Mod | 0.001 | 0.002 |
| Flatulence-non-SAE-Mod | 0.001 | 0 |
| Flushing-non-SAE-Mod | 0 | 0.002 |
| Folliculitis-non-SAE-Mild | 0.001 | 0 |
| Food Poisoning-non-SAE-Mild | 0.001 | 0 |
| Food Poisoning-non-SAE-Mod | 0.001 | 0 |
| Foot Fracture-non-SAE-Mod | 0.001 | 0 |
| Free Haemoglobin Present-non-SAE-Mild | 0.001 | 0 |
| Free Haemoglobin Present-non-SAE-Mod | 0.001 | 0 |
| Frequent Bowel Movements-non-SAE-Mod | 0.001 | 0 |
| Fungal Infection-non-SAE-Mild | 0.001 | 0.002 |
| Fungal Skin Infection-non-SAE-Mild | 0.001 | 0 |
Categories presented as Preferred term-Seriousness-Severity. The following codes are to be used: Seriousness: non-SAE-non-serious AE; SAE-serious AE Severity: Mild; Mod (Moderate); Sev (Severe)
| Number of AEs per infusion | IGSC, 10% - rHuPH20 | Safety Follow-up - IGSC, 10% or IGIV, 10% Only |
|---|---|---|
| Gastric Stenosis-non-SAE-Mod | 0.001 | 0 |
| Gastritis-non-SAE-Mild | 0.001 | 0 |
| Gastroenteritis-non-SAE-Mild | 0.002 | 0 |
| Gastroenteritis-non-SAE-Mod | 0.001 | 0 |
| Gastroenteritis Salmonella-non-SAE-Mod | 0.001 | 0 |
| Gastroenteritis Viral-non-SAE-Mild | 0.003 | 0.002 |
| Gastroenteritis Viral-non-SAE-Mod | 0.002 | 0.002 |
| Gastrointestinal Viral Infection-non-SAE-Mild | 0.001 | 0 |
| Gastrooesophageal Reflux Disease-non-SAE-Mild | 0.002 | 0 |
| Gastrooesophageal Reflux Disease-non-SAE-Mod | 0.001 | 0 |
| Genital Herpes-non-SAE-Mild | 0.001 | 0.003 |
| Genital Herpes-non-SAE-Mod | 0 | 0.002 |
| Gingival Erosion-non-SAE-Mild | 0.001 | 0 |
| Gingivitis-non-SAE-Mild | 0.001 | 0 |
| Glaucoma-non-SAE-Mod | 0.001 | 0 |
| Glycosuria-non-SAE-Mild | 0.001 | 0 |
| Gout-non-SAE-Mod | 0.001 | 0 |
| Haematochezia-non-SAE-Mild | 0.001 | 0 |
| Haematospermia-non-SAE-Mild | 0.001 | 0 |
| Haematuria-non-SAE-Mild | 0.001 | 0.002 |
| Haemoglobin Decreased-non-SAE-Mild | 0 | 0.002 |
| Haemolysis-non-SAE-Mild | 0.001 | 0 |
| Haemorrhoids-non-SAE-Mild | 0.001 | 0 |
| Haemorrhoids-non-SAE-Mod | 0.001 | 0 |
| Hand Fracture-non-SAE-Mod | 0.001 | 0 |
| Headache-non-SAE-Mild | 0.026 | 0.065 |
| Headache-non-SAE-Mod | 0.004 | 0.003 |
| Heart Rate Irregular-non-SAE-Mild | 0.001 | 0.002 |
| Herpes Zoster-non-SAE-Mod | 0.002 | 0 |
| Hiatus Hernia-non-SAE-Mild | 0.001 | 0 |
| Hydrocele-non-SAE-Mild | 0.001 | 0 |
| Hypercapnia-non-SAE-Mild | 0.001 | 0 |
| Hypercholesterolaemia-non-SAE-Mild | 0.001 | 0 |
| Hypersensitivity-non-SAE-Mild | 0.001 | 0 |
| Hypertension-non-SAE-Mild | 0.001 | 0.002 |
| Hypertension-non-SAE-Mod | 0.004 | 0 |
| Hypertension-SAE-Mod | 0.001 | 0 |
| Hypoaesthesia-non-SAE-Mild | 0.001 | 0 |
| Hypokalaemia-non-SAE-Mild | 0 | 0.003 |
| Hypothyroidism-non-SAE-Mild | 0 | 0.003 |
| Hypothyroidism-non-SAE-Mod | 0.001 | 0 |
| Impetigo-non-SAE-Mild | 0.001 | 0 |
| Incision Site Pain-non-SAE-Mod | 0.001 | 0 |
| Increased Upper Airway Secretion-non-SAE-Mild | 0.001 | 0 |
| Inflammation Of Wound-non-SAE-Mild | 0 | 0.002 |
| Influenza-non-SAE-Mod | 0.004 | 0.007 |
| Influenza Like Illness-non-SAE-Mild | 0.002 | 0 |
| Influenza Like Illness-non-SAE-Mod | 0.001 | 0 |
| Infusion Site Abscess-non-SAE-Mild | 0.001 | 0 |
| Infusion Site Bruising-non-SAE-Mild | 0.001 | 0 |
| Infusion Site Discolouration-non-SAE-Mild | 0.001 | 0 |
| Infusion Site Discomfort-non-SAE-Mild | 0.005 | 0.003 |
| Infusion Site Erythema-non-SAE-Mild | 0.014 | 0 |
| Infusion Site Erythema-non-SAE-Mod | 0.001 | 0 |
| Infusion Site Induration-non-SAE-Mild | 0.001 | 0 |
| Infusion Site Mass-non-SAE-Mild | 0.001 | 0 |
| Infusion Site Oedema-non-SAE-Mild | 0.001 | 0 |
| Infusion Site Pain-non-SAE-Mild | 0.049 | 0.028 |
| Infusion Site Pain-non-SAE-Mod | 0.004 | 0.003 |
| Infusion Site Pruritus-non-SAE-Mild | 0.019 | 0 |
| Infusion Site Swelling-non-SAE-Mild | 0.002 | 0 |
| Infusion Site Swelling-non-SAE-Sev | 0.001 | 0 |
| Injection Site Pain-non-SAE-Mild | 0.002 | 0 |
| Insomnia-non-SAE-Mild | 0.003 | 0 |
| Insomnia-non-SAE-Mod | 0 | 0.002 |
| Intervertebral Disc Degeneration-non-SAE-Mild | 0.001 | 0 |
| Iron Deficiency Anaemia-non-SAE-Mild | 0.001 | 0 |
| Irritable Bowel Syndrome-non-SAE-Mod | 0.001 | 0 |
| Jejunal Stenosis-non-SAE-Mod | 0.001 | 0 |
| Joint Dislocation-non-SAE-Sev | 0.001 | 0 |
| Joint Injury-non-SAE-Mild | 0.001 | 0 |
| Joint Swelling-non-SAE-Mod | 0 | 0.002 |
| Laceration-non-SAE-Mild | 0 | 0.002 |
| Ligament Sprain-non-SAE-Mild | 0.001 | 0 |
| Ligament Sprain-non-SAE-Mod | 0.001 | 0.003 |
| Limb Discomfort-non-SAE-Mild | 0 | 0.002 |
| Liver Function Test Abnormal-non-SAE-Mild | 0.001 | 0 |
| Local Swelling-non-SAE-Mild | 0.002 | 0 |
| Localised Infection-non-SAE-Mod | 0.001 | 0 |
| Loss Of Consciousness-non-SAE-Mild | 0 | 0.002 |
| Lyme Disease-non-SAE-Mild | 0.001 | 0 |
| Lymph Gland Infection-non-SAE-Mod | 0.001 | 0 |
| Lymphadenitis-non-SAE-Mod | 0 | 0.002 |
| Lymphadenitis Bacterial-non-SAE-Mild | 0.001 | 0 |
| Lymphadenopathy-non-SAE-Mild | 0.003 | 0.003 |
| Lymphopenia-non-SAE-Mild | 0.001 | 0 |
| Malaise-non-SAE-Mild | 0.002 | 0.002 |
| Medical Device Pain-non-SAE-Mild | 0.001 | 0 |
| Memory Impairment-non-SAE-Mild | 0.001 | 0 |
| Meniscus Injury-non-SAE-Mild | 0.001 | 0 |
| Menstrual Disorder-non-SAE-Mod | 0.001 | 0 |
| Mental Status Changes-SAE-Sev | 0.001 | 0 |
| Micturition Urgency-non-SAE-Mild | 0 | 0.002 |
| Middle Ear Effusion-non-SAE-Mild | 0 | 0.002 |
| Migraine-non-SAE-Mild | 0.003 | 0.003 |
| Migraine-non-SAE-Mod | 0.003 | 0.008 |
| Migraine-non-SAE-Sev | 0 | 0.002 |
| Mitral Valve Incompetence-non-SAE-Mild | 0.001 | 0 |
| Molluscum Contagiosum-non-SAE-Mild | 0.001 | 0.002 |
| Mouth Ulceration-non-SAE-Mild | 0 | 0.002 |
| Mucosal Inflammation-non-SAE-Mild | 0.001 | 0 |
| Muscle Contractions Involuntary-non-SAE-Mild | 0.001 | 0 |
| Muscle Spasms-non-SAE-Mild | 0.003 | 0 |
| Muscle Strain-non-SAE-Mild | 0.001 | 0 |
| Muscular Weakness-non-SAE-Mild | 0 | 0.002 |
| Muscular Weakness-non-SAE-Mod | 0.001 | 0 |
| Musculoskeletal Pain-non-SAE-Mild | 0.003 | 0 |
| Musculoskeletal Pain-non-SAE-Mod | 0.001 | 0.002 |
| Myalgia-non-SAE-Mild | 0.016 | 0.010 |
| Myalgia-non-SAE-Mod | 0.002 | 0.003 |
Categories presented as Preferred term-Seriousness-Severity. The following codes are to be used: Seriousness: non-SAE-non-serious AE; SAE-serious AE Severity: Mild; Mod (Moderate); Sev (Severe)
| Number of AEs per infusion | IGSC, 10% - rHuPH20 | Safety Follow-up - IGSC, 10% or IGIV, 10% Only |
|---|---|---|
| Nasal Congestion-non-SAE-Mild | 0.007 | 0.008 |
| Nasal Congestion-non-SAE-Mod | 0.001 | 0 |
| Nasal Discomfort-non-SAE-Mild | 0.001 | 0 |
| Nasopharyngitis-non-SAE-Mild | 0.004 | 0.008 |
| Nasopharyngitis-non-SAE-Mod | 0.001 | 0 |
| Nausea-non-SAE-Mild | 0.024 | 0.028 |
| Nausea-non-SAE-Mod | 0.004 | 0.013 |
| Nephrolithiasis-non-SAE-Mild | 0 | 0.002 |
| Nerve Compression-non-SAE-Mild | 0 | 0.002 |
| Neutrophil Count Decreased-non-SAE-Mild | 0 | 0.002 |
| Ocular Hyperaemia-non-SAE-Mild | 0 | 0.002 |
| Oedema Peripheral-non-SAE-Mild | 0.003 | 0.008 |
| Oedema Peripheral-non-SAE-Mod | 0.003 | 0.002 |
| Oral Candidiasis-non-SAE-Mild | 0.001 | 0 |
| Oral Herpes-non-SAE-Mild | 0.004 | 0.003 |
| Oral Pain-non-SAE-Mild | 0 | 0.002 |
| Oral Pain-non-SAE-Mod | 0 | 0.002 |
| Orchitis-non-SAE-Mod | 0.001 | 0 |
| Oropharyngeal Pain-non-SAE-Mild | 0.003 | 0.002 |
| Osteoarthritis-non-SAE-Mild | 0.001 | 0.002 |
| Osteoarthritis-non-SAE-Mod | 0.001 | 0 |
| Osteopenia-non-SAE-Mild | 0.001 | 0 |
| Osteoporosis-non-SAE-Mild | 0 | 0.002 |
| Otitis Externa-non-SAE-Mild | 0.001 | 0.002 |
| Otitis Externa-non-SAE-Mod | 0 | 0.002 |
| Otitis Media-non-SAE-Mod | 0.001 | 0.002 |
| Pain-non-SAE-Mild | 0.006 | 0 |
| Pain In Extremity-non-SAE-Mild | 0.003 | 0.002 |
| Pain In Extremity-non-SAE-Sev | 0 | 0.002 |
| Palpitations-non-SAE-Mild | 0.001 | 0 |
| Panic Attack-non-SAE-Mild | 0 | 0.002 |
| Papule-non-SAE-Mild | 0.001 | 0 |
| Paraesthesia-non-SAE-Mild | 0.001 | 0 |
| Paranasal Cyst-non-SAE-Mild | 0.001 | 0 |
| Pelvic Pain-non-SAE-Mod | 0.001 | 0 |
| Pericardial Effusion-non-SAE-Mild | 0.001 | 0 |
| Perineurial Cyst-non-SAE-Mod | 0.001 | 0 |
| Periodontal Disease-non-SAE-Mild | 0.001 | 0 |
| Pharyngitis-non-SAE-Mild | 0.004 | 0.002 |
| Pharyngitis-non-SAE-Mod | 0 | 0.002 |
| Pharyngitis Streptococcal-non-SAE-Mild | 0.001 | 0 |
| Pleural Effusion-non-SAE-Mild | 0.001 | 0 |
| Pleural Effusion-non-SAE-Mod | 0.001 | 0 |
| Pneumonia-non-SAE-Mild | 0.001 | 0 |
| Pneumonia Bacterial-non-SAE-Mod | 0.001 | 0 |
| Pneumonia Pseudomonas Aeruginosa-SAE-Sev | 0.001 | 0 |
| Pollakiuria-non-SAE-Mild | 0 | 0.002 |
| Pollakiuria-non-SAE-Mod | 0.001 | 0 |
| Polycystic Ovaries-non-SAE-Mild | 0 | 0.002 |
| Post Procedural Complication-non-SAE-Mod | 0.001 | 0 |
| Post Procedural Haemorrhage-non-SAE-Mild | 0.001 | 0 |
| Post Procedural Swelling-non-SAE-Mild | 0.001 | 0 |
| Procedural Nausea-non-SAE-Mod | 0.001 | 0 |
| Procedural Pain-non-SAE-Mild | 0 | 0.002 |
| Procedural Pain-non-SAE-Mod | 0.006 | 0.002 |
| Proctalgia-non-SAE-Mod | 0.001 | 0 |
| Productive Cough-non-SAE-Mild | 0.001 | 0 |
| Protein Urine Present-non-SAE-Mild | 0.001 | 0 |
| Pruritus-non-SAE-Mild | 0.002 | 0.010 |
| Pruritus-non-SAE-Mod | 0.001 | 0 |
| Pruritus Allergic-non-SAE-Mod | 0 | 0.002 |
| Pruritus Generalised-non-SAE-Mild | 0 | 0.002 |
| Pulmonary Hypertension-non-SAE-Mild | 0.001 | 0 |
| Pulmonary Hypertension-non-SAE-Mod | 0.001 | 0 |
| Pulmonary Vascular Disorder-non-SAE-Mod | 0.001 | 0 |
| Puncture Site Pain-non-SAE-Mild | 0 | 0.002 |
| Puncture Site Pain-non-SAE-Mod | 0 | 0.003 |
| Purpura Senile-non-SAE-Mild | 0 | 0.002 |
| Pyogenic Granuloma-non-SAE-Mod | 0.001 | 0.002 |
| Pyrexia-non-SAE-Mild | 0.009 | 0.008 |
| Pyrexia-non-SAE-Mod | 0.001 | 0 |
| Pyuria-non-SAE-Mild | 0 | 0.002 |
| Rales-non-SAE-Mod | 0.001 | 0.002 |
| Rash-non-SAE-Mild | 0.001 | 0.002 |
| Rash Generalised-non-SAE-Mild | 0 | 0.002 |
| Rectal Polyp-non-SAE-Mod | 0.001 | 0 |
| Red Blood Cells Urine Positive-non-SAE-Mild | 0.001 | 0 |
| Respiratory Tract Congestion-non-SAE-Mild | 0.001 | 0 |
| Respiratory Tract Congestion-non-SAE-Mod | 0.001 | 0 |
| Respiratory Tract Infection-non-SAE-Mild | 0.001 | 0 |
| Respiratory Tract Infection-non-SAE-Mod | 0.001 | 0 |
| Restless Legs Syndrome-non-SAE-Mild | 0.001 | 0 |
| Rhinitis-non-SAE-Mild | 0.001 | 0 |
| Rhinitis Perennial-non-SAE-Mild | 0.001 | 0 |
| Rhinorrhoea-non-SAE-Mild | 0.001 | 0.003 |
| Right Atrial Dilatation-non-SAE-Mild | 0.001 | 0 |
| Rotator Cuff Syndrome-non-SAE-Mild | 0.001 | 0 |
| Scab-non-SAE-Mild | 0.001 | 0 |
| Scar-non-SAE-Mild | 0.001 | 0 |
| Scoliosis-non-SAE-Mild | 0 | 0.002 |
| Scratch-non-SAE-Mild | 0.001 | 0 |
| Scrotal Swelling-non-SAE-Mild | 0.002 | 0 |
| Seborrhoeic Keratosis-non-SAE-Mod | 0.001 | 0 |
| Sinus Congestion-non-SAE-Mild | 0.001 | 0.002 |
| Sinus Headache-non-SAE-Mild | 0.001 | 0 |
| Sinusitis-non-SAE-Mild | 0.021 | 0.005 |
| Sinusitis-non-SAE-Mod | 0.018 | 0.022 |
| Skin Hyperpigmentation-non-SAE-Mild | 0.001 | 0 |
| Skin Lesion-non-SAE-Mild | 0.001 | 0 |
| Skin Mass-non-SAE-Mild | 0.001 | 0.002 |
| Sleep Apnoea Syndrome-non-SAE-Mild | 0.001 | 0 |
| Slow Speech-non-SAE-Mod | 0.001 | 0 |
| Solar Lentigo-non-SAE-Mild | 0.001 | 0 |
| Somnolence-non-SAE-Mild | 0.001 | 0 |
| Speech Disorder-non-SAE-Mild | 0 | 0.002 |
| Spermatocele-non-SAE-Mild | 0.001 | 0 |
| Spinal Compression Fracture-non-SAE-Mod | 0.001 | 0 |
| Spinal Meningeal Cyst-SAE-Sev | 0.001 | 0 |
| Spinal Osteoarthritis-non-SAE-Mild | 0.002 | 0 |
| Squamous Cell Carcinoma-non-SAE-Mod | 0.003 | 0.003 |
| Stress-non-SAE-Mod | 0.001 | 0 |
| Suicide Attempt-non-SAE-Sev | 0.001 | 0 |
| Sunburn-non-SAE-Mild | 0.001 | 0 |
| Swelling Face-non-SAE-Mod | 0.001 | 0 |
| Swelling Face-non-SAE-Sev | 0 | 0.002 |
| Swollen Tongue-non-SAE-Mild | 0.001 | 0 |
| Synovial Cyst-non-SAE-Mild | 0.001 | 0 |
| Tachycardia-non-SAE-Mild | 0.003 | 0.002 |
| Tachycardia-non-SAE-Mod | 0.001 | 0 |
| Tendon Disorder-non-SAE-Sev | 0.001 | 0 |
| Tendonitis-non-SAE-Mild | 0.001 | 0 |
| Tendonitis-non-SAE-Mod | 0.001 | 0 |
| Testicular Microlithiasis-non-SAE-Mild | 0.001 | 0 |
| Testicular Pain-non-SAE-Mod | 0.001 | 0 |
| Thermal Burn-non-SAE-Mild | 0 | 0.002 |
| Thinking Abnormal-non-SAE-Mod | 0.001 | 0 |
| Thrombocytopenia-non-SAE-Mild | 0.001 | 0 |
| Tibia Fracture-non-SAE-Sev | 0.001 | 0 |
| Tinea Cruris-non-SAE-Mild | 0.001 | 0 |
| Tinea Infection-non-SAE-Mild | 0.001 | 0 |
| Tooth Abscess-non-SAE-Mild | 0 | 0.002 |
| Tooth Abscess-non-SAE-Mod | 0 | 0.002 |
| Tooth Fracture-non-SAE-Mod | 0.001 | 0 |
| Tooth Infection-non-SAE-Mild | 0.001 | 0 |
| Tooth Infection-non-SAE-Mod | 0.001 | 0 |
| Toothache-non-SAE-Mod | 0 | 0.002 |
| Toxicity To Various Agents-SAE-Sev | 0.001 | 0 |
| Tracheal Stenosis-non-SAE-Mild | 0 | 0.002 |
| Transient Ischaemic Attack-SAE-Mod | 0 | 0.002 |
| Traumatic Haematoma-non-SAE-Mild | 0.001 | 0 |
| Tricuspid Valve Incompetence-non-SAE-Mild | 0.001 | 0 |
| Trigeminal Neuralgia-non-SAE-Mild | 0.001 | 0 |
| Tympanic Membrane Scarring-non-SAE-Mild | 0.001 | 0 |
| Type 2 Diabetes Mellitus-non-SAE-Mod | 0.001 | 0 |
| Upper Limb Fracture-non-SAE-Mod | 0.001 | 0 |
| Upper Limb Fracture-non-SAE-Sev | 0.001 | 0 |
| Upper Respiratory Tract Infection-non-SAE-Mild | 0.010 | 0.013 |
| Upper Respiratory Tract Infection-non-SAE-Mod | 0.008 | 0.003 |
| Upper-Airway Cough Syndrome-non-SAE-Mild | 0.001 | 0.002 |
| Urethritis-non-SAE-Mild | 0.001 | 0 |
| Urinary Tract Infection-non-SAE-Mild | 0.003 | 0.007 |
| Urinary Tract Infection-non-SAE-Mod | 0.004 | 0.003 |
| Urticaria-non-SAE-Mild | 0 | 0.003 |
| Uterine Polyp-non-SAE-Mod | 0.001 | 0 |
| Vaginal Prolapse-SAE-Mod | 0.001 | 0 |
| Vaginitis Bacterial-non-SAE-Mild | 0.001 | 0 |
| Varicose Vein-non-SAE-Mild | 0.001 | 0 |
| Vasomotor Rhinitis-non-SAE-Mild | 0.001 | 0 |
| Vein Pain-non-SAE-Mild | 0 | 0.002 |
| Ventricular Hypokinesia-non-SAE-Mild | 0.001 | 0 |
| Vessel Puncture Site Bruise-non-SAE-Mild | 0.001 | 0 |
| Viral Infection-non-SAE-Mild | 0.002 | 0 |
| Viral Infection-non-SAE-Mod | 0 | 0.002 |
| Viral Pharyngitis-non-SAE-Mild | 0.001 | 0 |
| Viral Pharyngitis-non-SAE-Mod | 0 | 0.002 |
| Viral Rash-non-SAE-Mod | 0.001 | 0 |
| Viral Upper Respiratory Tract Inf.-non-SAE-Mild | 0.018 | 0.008 |
| Viral Upper Respiratory Tract Inf-non-SAE-Mod | 0.001 | 0.002 |
| Vision Blurred-non-SAE-Mild | 0.001 | 0 |
| Vitamin B12 Deficiency-non-SAE-Mild | 0.001 | 0 |
| Vitamin D Decreased-non-SAE-Mild | 0 | 0.002 |
| Vitamin D Deficiency-non-SAE-Mild | 0.001 | 0 |
| Vitamin D Deficiency-non-SAE-Mod | 0.001 | 0 |
| Vomiting-non-SAE-Mild | 0.008 | 0.003 |
| Vomiting-non-SAE-Mod | 0.003 | 0.003 |
| Vulvar Dysplasia-non-SAE-Mild | 0.001 | 0 |
| Vulvovaginal Candidiasis-non-SAE-Mild | 0.001 | 0 |
| Vulvovaginal Mycotic Infection-non-SAE-Mild | 0.003 | 0.002 |
| Vulvovaginal Mycotic Infection-non-SAE-Mod | 0.001 | 0 |
| Wheezing-non-SAE-Mod | 0.001 | 0 |
| Wisdom Teeth Removal-non-SAE-Mild | 0.001 | 0 |
| Wisdom Teeth Removal-non-SAE-Sev | 0.001 | 0 |
| Wound-non-SAE-Mild | 0 | 0.002 |
| Wrist Fracture-non-SAE-Mod | 0 | 0.002 |
| Xeroderma-non-SAE-Mild | 0.001 | 0 |
Categories presented as adverse event (AE) type : Total, Local, Systemic including infections, Systemic excluding infections, and Severity (Mild, Moderate, Severe, Total). All of these adverse events are non-serious AEs.
| Number of AEs per participant | IGSC, 10% - rHuPH20 | Safety Follow-up - IGSC, 10% or IGIV, 10% Only |
|---|---|---|
| Total AEs, Mild | 4.635 | 2.137 |
| Total AEs, Moderate | 0.476 | 0.392 |
| Total AEs, Severe | 0.016 | 0.059 |
| Total AEs, Total | 5.127 | 2.588 |
| Local nsAEs, Mild | 2.476 | 0.373 |
| Local AEs, Moderate | 0.111 | 0 |
| Local AEs, Severe | 0.016 | 0 |
| Local AEs, Total | 2.603 | 0.373 |
| Systemic AEs including infections, Mild | 2.159 | 1.765 |
| Systemic AEs including infections, Moderate | 0.365 | 0.392 |
| Systemic AEs including infections, Severe | 0 | 0.059 |
| Systemic AEs including infections, Total | 2.524 | 2.216 |
| Systemic AEs excluding infections, Mild | 2.159 | 1.765 |
| Systemic AEs excluding infections, Moderate | 0.365 | 0.392 |
| Systemic AEs excluding infections, Severe | 0 | 0.059 |
| Systemic AEs excluding infections, Total | 2.524 | 2.216 |
Categories presented as adverse event (AE) type : Total, Local, Systemic including infections, Systemic excluding infections, and Severity (Mild, Moderate, Severe, Total). All of these adverse events are non-serious AEs.
| Number of AEs per infusion | IGSC, 10% - rHuPH20 | Safety Follow-up - IGSC, 10% or IGIV, 10% Only |
|---|---|---|
| Total AEs, Mild | 0.183 | 0.182 |
| Total AEs, Moderate | 0.019 | 0.033 |
| Total AEs, Severe | 0.001 | 0.005 |
| Total AEs, Total | 0.202 | 0.221 |
| Local AEs, Mild | 0.098 | 0.032 |
| Local AEs, Moderate | 0.004 | 0 |
| Local AEs, Severe | 0.001 | 0 |
| Local AEs, Total | 0.103 | 0.032 |
| Systemic AEs including infections, Mild | 0.085 | 0.151 |
| Systemic AEs including infections, Moderate | 0.014 | 0.033 |
| Systemic AEs including infections, Severe | 0 | 0.005 |
| Systemic AEs including infections, Total | 0.099 | 0.189 |
| Systemic AEs excluding infections, Mild | 0.085 | 0.151 |
| Systemic AEs excluding infections, Moderate | 0.014 | 0.033 |
| Systemic AEs excluding infections, Severe | 0 | 0.005 |
| Systemic AEs excluding infections, Total | 0.099 | 0.189 |
Categories presented as adverse event (AE) type : Total, Local, Systemic including infections, Systemic excluding infections, Seriousness: Serious AE (SAE), non-serious AE (nsAE) and Severity (Mild, Moderate, Severe, Total). All of these adverse events are non-serious AEs.
| Number of AEs per participant | IGSC, 10% - rHuPH20 | Safety Follow-up - IGSC, 10% or IGIV, 10% Only |
|---|---|---|
| Total, nsAE, Mild | 5.921 | 2.275 |
| Total, nsAE, Moderate | 1.111 | 0.647 |
| Total, nsAE, Severe | 0.032 | 0.059 |
| Total nsAE, Total | 7.063 | 2.980 |
| Total, SAE, Moderate | 0.016 | 0 |
| Total, SAE, Severe | 0.016 | 0 |
| Total, SAE, Total | 0.032 | 0 |
| Local, nsAE, Mild | 2.492 | 0.353 |
| Local, nsAE, Moderate | 0.111 | 0.039 |
| Local, nsAE, Severe | 0.016 | 0 |
| Local, nsAE, Total | 2.619 | 0.392 |
| Systemic including infections, nsAE, Mild | 3.429 | 1.922 |
| Systemic including infections, nsAE, Moderate | 1.000 | 0.608 |
| Systemic including infections, nsAE, Severe | 0.016 | 0.059 |
| Systemic including infections, nsAE, Total | 4.444 | 2.588 |
| Systemic including infections, SAE, Moderate | 0.016 | 0 |
| Systemic including infections, SAE, Severe | 0.016 | 0 |
| Systemic including infections, SAE, Total | 0.032 | 0 |
| Systemic excluding infections, nsAE, Mild | 3.111 | 1.922 |
| Systemic excluding infections, nsAE, Moderate | 0.873 | 0.608 |
| Systemic excluding infections, nsAE, Severe | 0.016 | 0.059 |
| Systemic excluding infections, nsAE, Total | 4.000 | 2.588 |
| Systemic excluding infections, SAE, Moderate | 0.016 | 0 |
| Systemic excluding infections, SAE, Severe | 0.016 | 0 |
| Systemic excluding infections, SAE, Total | 0.032 | 0 |
Categories presented as adverse event (AE) type : Total, Local, Systemic including infections, Systemic excluding infections, Seriousness: Serious AE (SAE), non-serious AE (non-SAE) and Severity (Mild, Moderate, Severe, Total). All of these adverse events are non-serious AEs.
| Number of AEs per infusion | IGSC, 10% - rHuPH20 | Safety Follow-up - IGSC, 10% or IGIV, 10% Only |
|---|---|---|
| Total, non-SAE, Mild | 0.233 | 0.194 |
| Total, non-SAE, Moderate | 0.044 | 0.055 |
| Total, non-SAE, Severe | 0.001 | 0.005 |
| Total non-SAE, Total | 0.278 | 0.254 |
| Total, SAE, Moderate | 0.001 | 0 |
| Total, SAE, Severe | 0.001 | 0 |
| Total, SAE, Total | 0.001 | 0 |
| Local, non-SAE, Mild | 0.098 | 0.030 |
| Local, non-SAE, Moderate | 0.004 | 0.003 |
| Local, non-SAE, Severe | 0.001 | 0 |
| Local, non-SAE, Total | 0.103 | 0.033 |
| Systemic including infections, non-SAE, Mild | 0.135 | 0.164 |
| Systemic including infections, non-SAE, Moderate | 0.039 | 0.052 |
| Systemic including infections, non-SAE, Severe | 0.001 | 0.005 |
| Systemic including infections, non-SAE, Total | 0.175 | 0.221 |
| Systemic including infections, SAE, Moderate | 0.001 | 0 |
| Systemic including infections, SAE, Severe | 0.001 | 0 |
| Systemic including infections, SAE, Total | 0.001 | 0 |
| Systemic excluding infections, non-SAE, Mild | 0.123 | 0.156 |
| Systemic excluding infections, non-SAE, Moderate | 0.034 | 0.043 |
| Systemic excluding infections, non-SAE, Severe | 0.001 | 0.005 |
| Systemic excluding infections, non-SAE, Total | 0.158 | 0.204 |
| Systemic excluding infections, SAE, Moderate | 0.001 | 0 |
| Systemic excluding infections, SAE, Severe | 0.001 | 0 |
| Systemic excluding infections, SAE, Total | 0.001 | 0 |
| Percentage of infusions | IGSC, 10% - rHuPH20 | Safety Follow-up - IGSC, 10% or IGIV, 10% Only |
|---|---|---|
| Including Infections | 8.8 | 3.7 |
| Excluding Infections | 8.7 | 3.7 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IGSC, 10% - rHuPH20 | — | 9/63 (14.3%) | 60/63 (95.2%) |
| Safety Follow-up - IGSC, 10% or IGIV, 10% Only | — | 3/51 (5.9%) | 45/51 (88.2%) |
| Event | IGSC, 10% - rHuPH20 | Safety Follow-up - IGSC, 10% or IGIV, 10% Only |
|---|---|---|
| CellulitisInfections and infestations | 0/63 | 1/51 |
| Femur FractureInjury, poisoning and procedural complications | 0/63 | 1/51 |
| Transient Ischaemic AttackNervous system disorders | 0/63 | 1/51 |
| Aortic Valve IncompetenceCardiac disorders | 1/63 | 0/51 |
| Atrial FibrillationCardiac disorders | 1/63 | 0/51 |
| Cardiac Failure CongestiveCardiac disorders | 1/63 | 0/51 |
| AppendicitisInfections and infestations | 1/63 | 0/51 |
| Cryptosporidiosis InfectionInfections and infestations | 1/63 | 0/51 |
| Pneumonia Pseudomonas AeruginosaInfections and infestations | 1/63 | 0/51 |
| Toxicity to Various AgentsInjury, poisoning and procedural complications | 1/63 | 0/51 |
| Event | IGSC, 10% - rHuPH20 | Safety Follow-up - IGSC, 10% or IGIV, 10% Only |
|---|---|---|
| SinusitisInfections and infestations | 25/63 | 11/51 |
| HeadacheNervous system disorders | 24/63 | 10/51 |
| Upper Respiratory Tract InfectionInfections and infestations | 18/63 | 9/51 |
| NauseaGastrointestinal disorders | 16/63 | 4/51 |
| Infusion site PainGeneral disorders | 16/63 | 2/51 |
| Viral Upper Respiratory Tract InfectionInfections and infestations | 16/63 | 3/51 |
| BronchitisInfections and infestations | 14/63 | 6/51 |
| DiarrhoeaGastrointestinal disorders | 13/63 | 3/51 |
| VomitingGastrointestinal disorders | 13/63 | 2/51 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 13/63 | 6/51 |
Safety Analysis Set
| Age, Continuous(Years) | Participants Aged 2 to <12 Years | Participants Aged 12 to <16 Years | Participants Aged 16 to <65 Years | Participants Aged 65 Years and Older | Total |
|---|---|---|---|---|---|
| Median | 10.5 (9 to 11) | 15.0 (13 to 15) | 47.0 (16 to 64) | 71.0 (65 to 80) | 43.0 (9 to 80) |
| Sex: Female, Male(Participants) | Participants Aged 2 to <12 Years | Participants Aged 12 to <16 Years | Participants Aged 16 to <65 Years | Participants Aged 65 Years and Older | Total |
|---|---|---|---|---|---|
| Female | 1 | 1 | 23 | 7 | 32 |
| Male | 3 | 6 | 24 | 1 | 34 |
| Region of Enrollment(Participants) | Participants Aged 2 to <12 Years | Participants Aged 12 to <16 Years | Participants Aged 16 to <65 Years | Participants Aged 65 Years and Older | Total |
|---|---|---|---|---|---|
| United States | 4 | 7 | 47 | 8 | 66 |
Ran from Jul 2010 to primary completion in Aug 2013, 36 months.
Results were first posted in May 2016, 2 years 9 months after primary completion. A results delay was requested in Sep 2014.
Of 25 phase 3 interventional studies under Primary Immunodeficiency Diseases, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 41. This study's 36 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Primary Immunodeficiency Diseases →